George Bakris

Research Summary
Director, ASH Comprehensive Hypertension Center
Awards & Honors
  • 2009 - Honorary Doctorate Degree University of Thessaloniki Greece
  • 2012 - 2015 Top Doctors in USA Castle Connelly
  • 2014 - Astra Zeneca Award for Innovation in Therapeutics International Society of Hypertension
Publications
  1. Ruilope LM, Pitt B, Anker SD, Rossing P, Kovesdy CP, Pecoits-Filho R, Pergola P, Joseph A, Lage A, Mentenich N, Scheerer MF, Bakris GL. Kidney outcomes with finerenone: An analysis from the FIGARO-DKD study. Nephrol Dial Transplant. 2022 Apr 22. View in: PubMed

  2. Cohen S, Sternlicht H, Bakris GL. Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists. Curr Diab Rep. 2022 05; 22(5):213-218. View in: PubMed

  3. Lerma E, White WB, Bakris G. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease. Postgrad Med. 2022 Apr 20; 1-10. View in: PubMed

  4. Bakris GL, Mikami H, Hirata M, Nakajima A, Cressman MD. A Non-purine Xanthine Oxidoreductase Inhibitor Reduces Albuminuria in Patients with DKD: A Randomized Controlled Trial. Kidney360. 2021 Aug 26; 2(8):1240-1250. View in: PubMed

  5. Toto R, Bakris G. The FIDELIO Study Podcast. Diabetes Ther. 2022 May; 13(5):823-828. View in: PubMed

  6. Chiu N, Aggarwal R, Bakris GL, Pitt B, Bhatt DL. Generalizability of FIGARO-DKD and FIDELIO-DKD Trial Criteria to the US Population Eligible for Finerenone. J Am Heart Assoc. 2022 Apr 05; 11(7):e025079. View in: PubMed

  7. DeFronzo RA, Bakris GL. Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes. Diabetes Obes Metab. 2022 Mar 18. View in: PubMed

  8. Filippatos G, Pitt B, Agarwal R, Farmakis D, Ruilope LM, Rossing P, Bauersachs J, Mentz RJ, Kolkhof P, Scott C, Joseph A, Bakris GL, Anker SD. Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. Eur J Heart Fail. 2022 Mar 03. View in: PubMed

  9. Liao J, Kang A, Xia C, Young T, Di Tanna GL, Arnott C, Pollock C, Krishnan AV, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Heerspink HJL, Levin A, Neal B, Wheeler DC, Zhang H, Zinman B, Mahaffey KW, Perkovic V, Jardine MJ, Smyth B. The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial. Diabetes Metab. 2022 Feb 13; 48(4):101331. View in: PubMed

  10. Zemke AM, Rodby RA, Hertl M, Waleed A, Bakris GL. Successful treatment of refractory hypertension with bilateral nephrectomy in a patient with chronic kidney disease stage 3. Clin Kidney J. 2022 Feb; 15(2):347-350. View in: PubMed

  11. van Kleef MEAM, Devireddy CM, van der Heyden J, Bates MC, Bakris GL, Stone GW, Williams B, Spiering W. Treatment of Resistant Hypertension With Endovascular Baroreflex Amplification: 3-Year Results From the CALM-FIM Study. JACC Cardiovasc Interv. 2022 02 14; 15(3):321-332. View in: PubMed

  12. Charytan DM, Yu J, Jardine MJ, Cannon CP, Agarwal R, Bakris G, Greene T, Levin A, Pollock C, Powe NR, Arnott C, Mahaffey KW. Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial. Clin J Am Soc Nephrol. 2022 03; 17(3):361-373. View in: PubMed

  13. Rossing P, Burgess E, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM, Gillard P, MacIsaac RJ, Wainstein J, Joseph A, Brinker M, Roessig L, Scott C, Bakris GL. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care. 2022 04 01; 45(4):888-897. View in: PubMed

  14. Stavas J, Gerber D, Coca SG, Silva AL, Johns A, Jain D, Bertram T, Díaz-González de Ferris M, Bakris G. Novel Renal Autologous Cell Therapy for Type 2 Diabetes Mellitus Chronic Diabetic Kidney Disease: Clinical Trial Design. Am J Nephrol. 2022; 53(1):50-58. View in: PubMed

  15. Salvador VD, Bakris GL. Identifying Resistant Hypertension in the Population: The Devil Is in the Details. Can J Cardiol. 2022 May; 38(5):555-556. View in: PubMed

  16. Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, Bakris GL. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022 Feb 10; 43(6):474-484. View in: PubMed

  17. Rossing P, Filippatos G, Agarwal R, Anker SD, Pitt B, Ruilope LM, Chan JCN, Kooy A, McCafferty K, Schernthaner G, Wanner C, Joseph A, Scheerer MF, Scott C, Bakris GL. Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy. Kidney Int Rep. 2022 Jan; 7(1):36-45. View in: PubMed

  18. Khan MS, Bakris GL, Shahid I, Weir MR, Butler J. Potential Role and Limitations of Estimated Glomerular Filtration Rate Slope Assessment in Cardiovascular Trials: A Review. JAMA Cardiol. 2022 May 01; 7(5):549-555. View in: PubMed

  19. Khan MS, Bakris GL, Packer M, Shahid I, Anker SD, Fonarow GC, Wanner C, Weir MR, Zannad F, Butler J. Kidney function assessment and endpoint ascertainment in clinical trials. Eur Heart J. 2022 04 06; 43(14):1379-1400. View in: PubMed

  20. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S185-S194. View in: PubMed

  21. 16. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S244-S253. View in: PubMed

  22. Summary of Revisions: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S4-S7. View in: PubMed

  23. 3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S39-S45. View in: PubMed

  24. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S17-S38. View in: PubMed

  25. 11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S175-S184. View in: PubMed

  26. 1. Improving Care and Promoting Health in Populations: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S8-S16. View in: PubMed

  27. 7. Diabetes Technology: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S97-S112. View in: PubMed

  28. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S46-S59. View in: PubMed

  29. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S83-S96. View in: PubMed

  30. 5. Facilitating Behavior Change and Well-being to Improve Health Outcomes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S60-S82. View in: PubMed

  31. 14. Children and Adolescents: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S208-S231. View in: PubMed

  32. 15. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S232-S243. View in: PubMed

  33. 13. Older Adults: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S195-S207. View in: PubMed

  34. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S113-S124. View in: PubMed

  35. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S125-S143. View in: PubMed

  36. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S144-S174. View in: PubMed

  37. Handelsman Y, Anderson JE, Bakris GL, Ballantyne CM, Beckman JA, Bhatt DL, Bloomgarden ZT, Bozkurt B, Budoff MJ, Butler J, Dagogo-Jack S, de Boer IH, DeFronzo RA, Eckel RH, Einhorn D, Fonseca VA, Green JB, Grunberger G, Guerin C, Inzucchi SE, Jellinger PS, Kosiborod MN, Kushner P, Lepor N, Mende CW, Michos ED, Plutzky J, Taub PR, Umpierrez GE, Vaduganathan M, Weir MR. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2022 02; 36(2):108101. View in: PubMed

  38. Al Dhaybi O, Bakris GL. Mineralocorticoid Receptor Antagonists-Evidence for Kidney Protection, Trials With Novel Agents. Adv Chronic Kidney Dis. 2021 07; 28(4):371-377. View in: PubMed

  39. Shaman AM, Bain SC, Bakris GL, Buse JB, Idorn T, Mahaffey KW, Mann JFE, Nauck MA, Rasmussen S, Rossing P, Wolthers B, Zinman B, Perkovic V. Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. Circulation. 2022 02 22; 145(8):575-585. View in: PubMed

  40. Ferreira JP, Rossignol P, Bakris G, Mehta C, White WB, Zannad F. Blood and Urine Biomarkers Predicting Worsening Kidney Function in Patients with Type 2 Diabetes Post-Acute Coronary Syndrome: An Analysis from the EXAMINE Trial. Am J Nephrol. 2021; 52(12):969-976. View in: PubMed

  41. Waijer SW, Gansevoort RT, Bakris GL, Correa-Rotter R, Hou FF, Kohan DE, Kitzman DW, Makino H, McMurray JJV, Perkovic V, Tobe S, Parving HH, de Zeeuw D, Heerspink HJL. The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Randomized Trial. Clin J Am Soc Nephrol. 2021 Dec 01. View in: PubMed

  42. Agarwal R, Anker SD, Filippatos G, Pitt B, Rossing P, Ruilope LM, Boletis J, Toto R, Umpierrez GE, Wanner C, Wada T, Scott C, Joseph A, Ogbaa I, Roberts L, Scheerer MF, Bakris GL. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post-hoc analyses from FIDELIO-DKD compared to reported CREDENCE results. Nephrol Dial Transplant. 2021 Nov 25. View in: PubMed

  43. Al Dhaybi O, Bakris GL. Factitious acidosis and severe hypoalbuminemia caused by unsuspected assay interference. Clin Kidney J. 2021 Mar; 14(3):1023-1024. View in: PubMed

  44. Kintscher U, Bakris GL, Kolkhof P. Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol. 2021 Nov 22. View in: PubMed

  45. Filippatos G, Anker SD, Agarwal R, Ruilope LM, Rossing P, Bakris GL, Tasto C, Joseph A, Kolkhof P, Lage A, Pitt B. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. Circulation. 2022 02 08; 145(6):437-447. View in: PubMed

  46. Agarwal R, Joseph A, Anker SD, Filippatos G, Rossing P, Ruilope LM, Pitt B, Kolkhof P, Scott C, Lawatscheck R, Wilson DJ, Bakris GL. Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. J Am Soc Nephrol. 2022 01; 33(1):225-237. View in: PubMed

  47. Kaneko H, Yano Y, Itoh H, Morita K, Kiriyama H, Kamon T, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Nishiyama A, Node K, Bakris G, Miura K, Muntner P, Viera AJ, Oparil S, Lloyd-Jones DM, Yasunaga H, Komuro I. Untreated Hypertension and Subsequent Incidence of Colorectal Cancer: Analysis of a Nationwide Epidemiological Database. J Am Heart Assoc. 2021 11 16; 10(22):e022479. View in: PubMed

  48. Barrera-Chimal J, Lima-Posada I, Bakris GL, Jaisser F. Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects. Nat Rev Nephrol. 2022 01; 18(1):56-70. View in: PubMed

  49. Salvador VD, Bakris GL. Longitudinal Blood Pressure Patterns and Chronic Kidney Disease Progression: An Evolving Paradigm. Hypertension. 2021 11; 78(5):1365-1367. View in: PubMed

  50. Pitt B, Jaisser F, Bakris G. An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension. Expert Opin Investig Drugs. 2021 Oct; 30(10):1017-1023. View in: PubMed

  51. Rossing P, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM, Amod A, Marre M, Joseph A, Lage A, Scott C, Bakris GL. Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial. Diabetes Obes Metab. 2022 01; 24(1):125-134. View in: PubMed

  52. Heerspink HJL, Xie D, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Perkovic V, Rossing P, Parving HH, de Zeeuw D. Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial. J Am Soc Nephrol. 2021 11; 32(11):2900-2911. View in: PubMed

  53. Ferreira JP, Rossignol P, Bakris G, Mehta C, White WB, Zannad F. Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial. Cardiovasc Diabetol. 2021 09 14; 20(1):187. View in: PubMed

  54. Filippatos G, Agarwal R, Bakris G, Anker S. Response by Filippatos et al to Letter Regarding Article, "Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes". Circulation. 2021 09 14; 144(11):e202-e203. View in: PubMed

  55. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021 12 09; 385(24):2252-2263. View in: PubMed

  56. Neuen BL, Oshima M, Perkovic V, Agarwal R, Arnott C, Bakris G, Cannon CP, Charytan DM, Edwards R, Górriz JL, Jardine MJ, Levin A, Neal B, De Nicola L, Pollock C, Rosenthal N, Wheeler DC, Mahaffey KW, Heerspink HJL. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. Eur Heart J. 2021 12 21; 42(48):4891-4901. View in: PubMed

  57. Kandzari DE, Townsend RR, Bakris G, Basile J, Bloch MJ, Cohen DL, East C, Ferdinand KC, Fisher N, Kirtane A, Lee DP, Puckrein G, Rader F, Vassalotti JA, Weber MA, Willis K, Secemsky E. Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by SCAI and NKF. Catheter Cardiovasc Interv. 2021 09; 98(3):416-426. View in: PubMed

  58. Ali W, Nathan S, Funaki B, Eggener S, Bakris G. An Unusual Case of Resistant Hypertension Secondary to Fibromuscular Dysplasia. JACC Case Rep. 2020 Dec; 2(15):2460-2464. View in: PubMed

  59. Laffin LJ, Bakris GL. Intersection Between Chronic Kidney Disease and Cardiovascular Disease. Curr Cardiol Rep. 2021 07 16; 23(9):117. View in: PubMed

  60. Laffin LJ, Bakris GL. Approach to Resistant Hypertension from Cardiology and Nephrology Standpoints: Tailoring Therapy. Cardiol Clin. 2021 Aug; 39(3):377-387. View in: PubMed

  61. Morgan ES, Tami Y, Hu K, Brambatti M, Mullick AE, Geary RS, Bakris GL, Tsimikas S. Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx: Results of Phase 1 and Phase 2 Studies. JACC Basic Transl Sci. 2021 Jun; 6(6):485-496. View in: PubMed

  62. Pulipati VP, Mares JW, Bakris GL. Optimizing Blood Pressure Control Without Adding Anti-Hypertensive Medications. Am J Med. 2021 10; 134(10):1195-1198. View in: PubMed

  63. Bakris GL, Woods SD, Alvarez PJ, Arthur SP, Kumar R. Hyperkalemia Management in Older Adults With Diabetic Kidney Disease Receiving Renin-Angiotensin-Aldosterone System Inhibitors: A Post Hoc Analysis of the AMETHYST-DN Clinical Trial. Kidney Med. 2021 May-Jun; 3(3):360-367.e1. View in: PubMed

  64. Filippatos G, Bakris GL, Pitt B, Agarwal R, Rossing P, Ruilope LM, Butler J, Lam CSP, Kolkhof P, Roberts L, Tasto C, Joseph A, Anker SD. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. J Am Coll Cardiol. 2021 07 13; 78(2):142-152. View in: PubMed

  65. Polonsky TS, Bakris GL. Systolic Blood Pressure During Exercise Testing: Where the Valley Means More Than the Peak. Hypertension. 2021 06; 77(6):1915-1917. View in: PubMed

  66. Bakris G, Pergola PE, Delgado B, Genov D, Doliashvili T, Vo N, Yang YF, McCabe J, Benn V, Pitt B. Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study. Hypertension. 2021 07; 78(1):74-81. View in: PubMed

  67. Rossello X, Ferreira JP, Caimari F, Lamiral Z, Sharma A, Mehta C, Bakris G, Cannon CP, White WB, Zannad F. Influence of sex, age and race on coronary and heart failure events in patients with diabetes and post-acute coronary syndrome. Clin Res Cardiol. 2021 Oct; 110(10):1612-1624. View in: PubMed

  68. Arnott C, Li JW, Cannon CP, de Zeeuw D, Neuen BL, Heerspink HJL, Charytan DM, Agarwal A, Huffman MD, Figtree GA, Bakris G, Chang TI, Feng K, Rosenthal N, Zinman B, Jardine MJ, Perkovic V, Neal B, Mahaffey KW. The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial. Diabetes Obes Metab. 2021 07; 23(7):1652-1659. View in: PubMed

  69. Bakris GL, Agarwal R, Filippatos G. Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes. Reply. N Engl J Med. 2021 03 18; 384(11):e42. View in: PubMed

  70. Bakris G, Sternlicht H. Time in Therapeutic Range: Redefining "Optimal" Blood Pressure Control. J Am Coll Cardiol. 2021 03 16; 77(10):1300-1301. View in: PubMed

  71. Ferreira JP, Lamiral Z, Bakris G, Mehta C, White WB, Zannad F. Red cell distribution width in patients with diabetes and myocardial infarction: An analysis from the EXAMINE trial. Diabetes Obes Metab. 2021 07; 23(7):1580-1587. View in: PubMed

  72. Jardine M, Zhou Z, Lambers Heerspink HJ, Hockham C, Li Q, Agarwal R, Bakris GL, Cannon CP, Charytan DM, Greene T, Levin A, Li JW, Neuen BL, Neal B, Oh R, Oshima M, Pollock C, Wheeler DC, de Zeeuw D, Zhang H, Zinman B, Mahaffey KW, Perkovic V. Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis. Clin J Am Soc Nephrol. 2021 03 08; 16(3):384-395. View in: PubMed

  73. Riddle MC, Bakris G, Blonde L, Boulton AJM, D'Alessio D, DiMeglio LA, Gonder-Frederick L, Hood KK, Hu FB, Kahn SE, Kaul S, Leiter LA, Moses RG, Rich SS, Rosenstock J, Wylie-Rosett J. A Lesson From 2020: Public Health Matters for Both COVID-19 and Diabetes. Diabetes Care. 2021 01; 44(1):8-10. View in: PubMed

  74. Ye N, Jardine MJ, Oshima M, Hockham C, Heerspink HJL, Agarwal R, Bakris G, Schutte AE, Arnott C, Chang TI, Górriz JL, Cannon CP, Charytan DM, de Zeeuw D, Levin A, Mahaffey KW, Neal B, Pollock C, Wheeler DC, Luca Di Tanna G, Cheng H, Perkovic V, Neuen BL. Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial. Circulation. 2021 05 04; 143(18):1735-1749. View in: PubMed

  75. Sarraju A, Li J, Cannon CP, Chang TI, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Greene T, Heerspink HJL, Levin A, Neal B, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Perkovic V, Jardine M, Mahaffey KW. Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. Am Heart J. 2021 03; 233:141-148. View in: PubMed

  76. Koomen JV, Stevens J, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan DE, Makino H, McMurray JJV, Parving HH, Perkovic V, Tobe SW, de Zeeuw D, Heerspink HJL. Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease. Clin Pharmacol Ther. 2021 06; 109(6):1631-1638. View in: PubMed

  77. Hanrahan JP, de Boer IH, Bakris GL, Wilson PJ, Wakefield JD, Seferovic JP, Chickering JG, Chien YT, Carlson K, Cressman MD, Currie MG, Milne GT, Profy AT. Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial. Clin J Am Soc Nephrol. 2020 12 31; 16(1):59-69. View in: PubMed

  78. Oshima M, Jardine MJ, Agarwal R, Bakris G, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Levin A, Lim SK, Mahaffey KW, Neal B, Pollock C, Rosenthal N, Wheeler DC, Zhang H, Zinman B, Perkovic V, Heerspink HJL. Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. Kidney Int. 2021 04; 99(4):999-1009. View in: PubMed

  79. Aggarwal R, Lu K, Chiu N, Bakris GL, Bhatt DL. U.S. Prevalence of Individuals With Diabetes and Chronic Kidney Disease Indicated for SGLT-2 Inhibitor Therapy. J Am Coll Cardiol. 2020 12 15; 76(24):2907-2910. View in: PubMed

  80. Agarwal R, Anker SD, Bakris G, Filippatos G, Pitt B, Rossing P, Ruilope L, Gebel M, Kolkhof P, Nowack C, Joseph A. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. Nephrol Dial Transplant. 2020 Dec 06. View in: PubMed

  81. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 03; 383(23):2219-2229. View in: PubMed

  82. Brook RD, Kaciroti N, Bakris G, Dahlöf B, Pitt B, Velazquez E, Weber MA, Jamerson KA. Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension. Am J Hypertens. 2021 05 22; 34(5):531-539. View in: PubMed

  83. Bakris G, Oshima M, Mahaffey KW, Agarwal R, Cannon CP, Capuano G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Neal B, Oh R, Pollock C, Rosenthal N, Wheeler DC, Zhang H, Zinman B, Jardine MJ, Perkovic V. Effects of Canagliflozin in Patients with Baseline eGFR PubMed

  84. Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Schloemer P, Tornus I, Joseph A, Bakris GL. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation. 2021 02 09; 143(6):540-552. View in: PubMed

  85. Koomen JV, Stevens J, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Parving HH, Perkovic V, Tobe SW, de Zeeuw D, Heerspink HJL. Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial. Diabetes Obes Metab. 2021 02; 23(2):561-568. View in: PubMed

  86. Kraus BJ, Weir MR, Bakris GL, Mattheus M, Cherney DZI, Sattar N, Heerspink HJL, Ritter I, von Eynatten M, Zinman B, Inzucchi SE, Wanner C, Koitka-Weber A. Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int. 2021 03; 99(3):750-762. View in: PubMed

  87. Bakris G. Stemming the Progression of Diabetic Kidney Disease: The Role of the Primary Care Clinician. J Fam Pract. 2020 09; 69(7 Suppl):S81-S86. View in: PubMed

  88. Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, Zannad F. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021 01 07; 42(2):152-161. View in: PubMed

  89. Oshima M, Neuen BL, Jardine MJ, Bakris G, Edwards R, Levin A, Mahaffey KW, Neal B, Pollock C, Rosenthal N, Wada T, Wheeler DC, Perkovic V, Heerspink HJL. Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. Lancet Diabetes Endocrinol. 2020 11; 8(11):903-914. View in: PubMed

  90. Elharram M, Sharma A, White W, Bakris G, Rossignol P, Mehta C, Ferreira JP, Zannad F. Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus. Am Heart J. 2020 11; 229:40-51. View in: PubMed

  91. Ferreira JP, Sharma A, Mehta C, Bakris G, Rossignol P, White WB, Zannad F. Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial. Clin Res Cardiol. 2021 Jul; 110(7):1006-1019. View in: PubMed

  92. Sarafidis P, Bakris G. Diastolic Blood Pressure Does Not Influence Cardiovascular Outcomes in Type 2 Diabetes; or Does It? Diabetes Care. 2020 08; 43(8):1684-1686. View in: PubMed

  93. Ali W, Bakris G. Evolution of Patiromer Use: a Review. Curr Cardiol Rep. 2020 07 09; 22(9):94. View in: PubMed

  94. Sternlicht HK, Bakris GL. Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes? Lancet Diabetes Endocrinol. 2020 07; 8(7):553-555. View in: PubMed

  95. Itano S, Yano Y, Nagasu H, Tomiyama H, Kanegae H, Makino H, Higashi Y, Kobayashi Y, Sogawa Y, Satoh M, Suzuki K, Townsend RR, Budoff M, Bakris G, Kashihara N. Association of Arterial Stiffness With Kidney Function Among Adults Without Chronic Kidney Disease. Am J Hypertens. 2020 11 03; 33(11):1003-1010. View in: PubMed

  96. Bakris G, Yang YF, Pitt B. Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial. Hypertension. 2020 07; 76(1):144-149. View in: PubMed

  97. Ferreira JP, Butler J, Rossignol P, Pitt B, Anker SD, Kosiborod M, Lund LH, Bakris GL, Weir MR, Zannad F. Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 06 09; 75(22):2836-2850. View in: PubMed

  98. Jardine MJ, Zhou Z, Mahaffey KW, Oshima M, Agarwal R, Bakris G, Bajaj HS, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Di Tanna GL, Greene T, Heerspink HJL, Levin A, Neal B, Pollock C, Qiu R, Sun T, Wheeler DC, Zhang H, Zinman B, Rosenthal N, Perkovic V. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. J Am Soc Nephrol. 2020 05; 31(5):1128-1139. View in: PubMed

  99. Ali W, Bakris GL. How to Manage Hypertension in People With Diabetes. Am J Hypertens. 2020 10 21; 33(10):935-943. View in: PubMed

  100. Al Dhaybi O, Bakris GL. Non-steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease. Diabetes Obes Metab. 2020 04; 22 Suppl 1:69-76. View in: PubMed

  101. Ali WE, Bakris GL. Fear of Lowering Cardiovascular Risk by Achieving Blood Pressure Goals: The Irrationality of Combination Therapy Avoidance. Hypertension. 2020 04; 75(4):943-944. View in: PubMed

  102. Bakris GL, Josephson MA. Improvement of Cardiovascular Functional Reserve After Kidney Transplant-Has the CAPER Been Solved? JAMA Cardiol. 2020 04 01; 5(4):430-431. View in: PubMed

  103. Ali W, Gao G, Bakris GL. Improved Sleep Quality Improves Blood Pressure Control among Patients with Chronic Kidney Disease: A Pilot Study. Am J Nephrol. 2020; 51(3):249-254. View in: PubMed

  104. Butler J, Handelsman Y, Bakris G, Verma S. Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure. Eur J Heart Fail. 2020 04; 22(4):604-617. View in: PubMed

  105. Idzerda NMA, Clegg LE, Hernandez AF, Bakris G, Penland RC, Boulton DW, Bethel MA, Holman RR, Heerspink HJL. Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL. Diabetes Obes Metab. 2020 05; 22(5):798-806. View in: PubMed

  106. Polonsky TS, Bakris GL. Paradoxical Cardiorenal Responses Following Acute Vasodilator/Natriuretic Treatment in Presystolic Heart Failure: Should We Be Surprised? JACC Basic Transl Sci. 2019 Dec; 4(8):973-975. View in: PubMed

  107. Sharma A, Vaduganathan M, Ferreira JP, Liu Y, Bakris GL, Cannon CP, White WB, Zannad F. Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial. J Am Heart Assoc. 2020 01 07; 9(1):e012797. View in: PubMed

  108. Bethel MA, Mentz RJ, Merrill P, Buse JB, Chan JC, Goodman SG, Iqbal N, Jakuboniene N, Katona B, Lokhnygina Y, Lopes RD, Maggioni AP, Ohman P, Tankova T, Bakris GL, Hernandez AF, Holman RR. Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. Diabetes Care. 2020 02; 43(2):446-452. View in: PubMed

  109. Prischl FC, Rossing P, Bakris G, Mayer G, Wanner C. Major adverse renal events (MARE): a proposal to unify renal endpoints. Nephrol Dial Transplant. 2021 02 20; 36(3):491-497. View in: PubMed

  110. Cannon CP, Perkovic V, Agarwal R, Baldassarre J, Bakris G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Jardine MJ, Levin A, Li JW, Neal B, Pollock C, Wheeler DC, Zhang H, Zinman B, Mahaffey KW. Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c PubMed

  111. Bakris G. Chronic Kidney Disease in Type 2 Diabetes: Optimizing Glucose-Lowering Therapy. J Fam Pract. 2019 10; 68(8):S1-S6. View in: PubMed

  112. Alexandrou ME, Papagianni A, Tsapas A, Loutradis C, Boutou A, Piperidou A, Papadopoulou D, Ruilope L, Bakris G, Sarafidis P. Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019 12; 37(12):2307-2324. View in: PubMed

  113. Ruilope LM, Agarwal R, Anker SD, Bakris GL, Filippatos G, Nowack C, Kolkhof P, Joseph A, Mentenich N, Pitt B. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. Am J Nephrol. 2019; 50(5):345-356. View in: PubMed

  114. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J Nephrol. 2019; 50(5):333-344. View in: PubMed

  115. Baliga RR, Bossone E, Bakris GL. Hypertensive Heart Failure: Sprinting to the Finish Line to Prevent End-Organ Damage. Heart Fail Clin. 2019 10; 15(4):xiii-xv. View in: PubMed

  116. Polonsky TS, Bakris GL. Heart Failure and Changes in Kidney Function: Focus on Understanding, Not Reacting. Heart Fail Clin. 2019 Oct; 15(4):455-461. View in: PubMed

  117. Rosenzweig JL, Bakris GL, Berglund LF, Hivert MF, Horton ES, Kalyani RR, Murad MH, Vergès BL. Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019 Jul 31. View in: PubMed

  118. Mahaffey KW, Jardine MJ, Bompoint S, Cannon CP, Neal B, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Capuano G, de Zeeuw D, Greene T, Levin A, Pollock C, Sun T, Wheeler DC, Yavin Y, Zhang H, Zinman B, Rosenthal N, Brenner BM, Perkovic V. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. Circulation. 2019 08 27; 140(9):739-750. View in: PubMed

  119. Koyner J, Bakris G. Kidney injury is not prevented by hydration alone. Eur Heart J. 2019 10 07; 40(38):3179-3181. View in: PubMed

  120. Bakris GL. Major Advancements in Slowing Diabetic Kidney Disease Progression: Focus on SGLT2 Inhibitors. Am J Kidney Dis. 2019 11; 74(5):573-575. View in: PubMed

  121. Bakris G, Ali W, Parati G. ACC/AHA Versus ESC/ESH on Hypertension Guidelines: JACC Guideline Comparison. J Am Coll Cardiol. 2019 06 18; 73(23):3018-3026. View in: PubMed

  122. Bakris GL, Laffin LJ. Assessing Wide Pulse Pressure Hypertension: Data Beyond the Guidelines. J Am Coll Cardiol. 2019 06 11; 73(22):2856-2858. View in: PubMed

  123. Ali W, Bakris G. The Management of Hypertension in 2018: What Should the Targets Be? Curr Hypertens Rep. 2019 04 25; 21(6):41. View in: PubMed

  124. Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019 05 11; 393(10184):1937-1947. View in: PubMed

  125. Bakris G, Sorrentino M. Perspective on the New Blood-Pressure Guidelines. Eur Heart J. 2018 Sep 01; 39(33):3008-3009. View in: PubMed

  126. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 06 13; 380(24):2295-2306. View in: PubMed

  127. Bakris G. Similarities and Differences Between the ACC/AHA and ESH/ESC Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Circ Res. 2019 03 29; 124(7):969-971. View in: PubMed

  128. Burnier M, Bakris G, Williams B. Redefining diuretics use in hypertension: why select a thiazide-like diuretic? J Hypertens. 2019 08; 37(8):1574-1586. View in: PubMed

  129. Vijayakumar S, Butler J, Bakris GL. Barriers to guideline mandated renin-angiotensin inhibitor use: focus on hyperkalaemia. Eur Heart J Suppl. 2019 Feb; 21(Suppl A):A20-A27. View in: PubMed

  130. Sternlicht H, Bakris GL. Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis. Curr Hypertens Rep. 2019 02 12; 21(2):12. View in: PubMed

  131. Cherney DZI, Bakris GL. Novel therapies for diabetic kidney disease. Kidney Int Suppl (2011). 2018 Jan; 8(1):18-25. View in: PubMed

  132. Bakris GL. Update on reducing the development of diabetic kidney disease and cardiovascular death in diabetes. Kidney Int Suppl (2011). 2018 Jan; 8(1):1. View in: PubMed

  133. Ihm SH, Bakris G, Sakuma I, Sohn IS, Koh KK. Controversies in the 2017 ACC/AHA Hypertension Guidelines: Who Can Be Eligible for Treatments Under the New Guidelines? - An Asian Perspective. Circ J. 2019 02 25; 83(3):504-510. View in: PubMed

  134. Parati G, Agabiti-Rosei E, Bakris GL, Bilo G, Branzi G, Cecchi F, Chrostowska M, De la Sierra A, Domenech M, Dorobantu M, Faria T, Huo Y, Jelakovic B, Kahan T, Konradi A, Laurent S, Li N, Madan K, Mancia G, McManus RJ, Modesti PA, Ochoa JE, Octavio JA, Omboni S, Palatini P, Park JB, Pellegrini D, Perl S, Podoleanu C, Pucci G, Redon J, Renna N, Rhee MY, Rodilla Sala E, Sanchez R, Schmieder R, Soranna D, Stergiou G, Stojanovic M, Tsioufis K, Valsecchi MG, Veglio F, Waisman GD, Wang JG, Wijnmaalen P, Zambon A, Zanchetti A, Zhang Y. MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol. BMJ Open. 2018 12 19; 8(12):e021038. View in: PubMed

  135. Bakris GL, Agarwal R. Creatinine Bump Following Antihypertensive Therapy. Hypertension. 2018 12; 72(6):1274-1276. View in: PubMed

  136. Vaduganathan M, White WB, Charytan DM, Morrow DA, Liu Y, Zannad F, Cannon CP, Bakris GL. Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial). Am J Cardiol. 2019 02 01; 123(3):382-391. View in: PubMed

  137. Hammes M, Bakris GL. Intradialytic Hypotension: Is Midodrine the Answer? Am J Nephrol. 2018; 48(5):378-380. View in: PubMed

  138. de Zeeuw D, Renfurm RW, Bakris G, Rossing P, Perkovic V, Hou FF, Nangaku M, Sharma K, Heerspink HJL, Garcia-Hernandez A, Larsson TE. Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2018 12; 6(12):925-933. View in: PubMed

  139. Polonsky TS, Bakris GL. Ambulatory Blood Pressure Monitoring. JAMA. 2018 Nov 06; 320(17):1807-1808. View in: PubMed

  140. White WB, Jalil F, Cushman WC, Bakris GL, Bergenstal R, Heller SR, Liu Y, Mehta C, Zannad F, Cannon CP. Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial. J Am Heart Assoc. 2018 10 16; 7(20):e009114. View in: PubMed

  141. Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, Egan BM, Flack JM, Gidding SS, Judd E, Lackland DT, Laffer CL, Newton-Cheh C, Smith SM, Taler SJ, Textor SC, Turan TN, White WB. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018 11; 72(5):e53-e90. View in: PubMed

  142. Laffin LJ, Bakris GL. Has the Sun Set on Nighttime Dosing in Uncomplicated Hypertension? Hypertension. 2018 10; 72(4):836-838. View in: PubMed

  143. Sarafidis PA, Loutradis C, Karpetas A, Tzanis G, Bikos A, Raptis V, Syrgkanis C, Liakopoulos V, Papagianni A, Bakris G, Parati G. The association of interdialytic blood pressure variability with cardiovascular events and all-cause mortality in haemodialysis patients. Nephrol Dial Transplant. 2020 07 01; 35(7):1277. View in: PubMed

  144. Ferdinand KC, Bakris GL, Cushman WC, Weber MA, Lloyd E, Wu J, White WB. Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension. Am J Cardiol. 2018 11 01; 122(9):1496-1505. View in: PubMed

  145. Bakris GL, Polonsky TS. Presence of Diabetes Does Not Mandate Lower Blood Pressure to Reduce Cardiovascular Events. J Am Coll Cardiol. 2018 09 11; 72(11):1224-1226. View in: PubMed

  146. Sarafidis PA, Loutradis C, Karpetas A, Tzanis G, Bikos A, Raptis V, Syrgkanis C, Liakopoulos V, Papagianni A, Bakris G, Parati G. The association of interdialytic blood pressure variability with cardiovascular events and all-cause mortality in haemodialysis patients. Nephrol Dial Transplant. 2019 03 01; 34(3):515-523. View in: PubMed

  147. Ali WE, Bakris GL. Initial single-pill combinations for antihypertensive treatment: greater cardiovascular mortality reduction yet still not used. Eur Heart J. 2018 10 21; 39(40):3662-3663. View in: PubMed

  148. Schlaich MP, Bakris GL. Renal denervation: one step backwards, three steps forward. Nat Rev Nephrol. 2018 10; 14(10):602-604. View in: PubMed

  149. Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, Fulcher G, Desai M, Li Q, Deng H, Rosenthal N, Jardine MJ, Bakris G, Perkovic V. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. Circulation. 2018 10 09; 138(15):1537-1550. View in: PubMed

  150. Riddle MC, Bakris G, Boulton AJM, Blonde L, D'Alessio D, Greene EL, de Groot M, Hood K, Hu FB, Kahn SE, Kaul S, LeRoith D, Moses RG, Rich SS, Rosenstock J, Tamborlane WV, Wylie-Rosett J, Reynolds L. Big Topics for Diabetes Care in 2018: Clinical Guidelines, Costs of Diabetes, and Information Technology. Diabetes Care. 2018 07; 41(7):1327-1329. View in: PubMed

  151. K Dojki F, Bakris GL. Hyperkalaemia in diabetes: a silent risk predicting poor outcomes. Diabet Med. 2018 08; 35(8):1049-1050. View in: PubMed

  152. Sharma A, Cannon CP, White WB, Liu Y, Bakris GL, Cushman WC, Zannad F. Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. J Am Heart Assoc. 2018 05 16; 7(11). View in: PubMed

  153. Pitt B, Bakris GL, Weir MR, Freeman MW, Lainscak M, Mayo MR, Garza D, Zawadzki R, Berman L, Bushinsky DA. Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN. ESC Heart Fail. 2018 08; 5(4):592-602. View in: PubMed

  154. Heerspink HJL, Andress DL, Bakris G, Brennan JJ, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray J, Perkovic V, Tobe S, Wigderson M, Yi T, Parving HH, de Zeeuw D. Baseline characteristics and enrichment results from the SONAR trial. Diabetes Obes Metab. 2018 08; 20(8):1829-1835. View in: PubMed

  155. Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cífková R, Dominiczak AF, Grassi G, Jordan J, Poulter NR, Rodgers A, Whelton PK. Hypertension. Nat Rev Dis Primers. 2018 03 22; 4:18014. View in: PubMed

  156. de Boer IH, Bakris GL. Diabetic Kidney Disease: A Determinant of Cardiovascular Risk in Type 1 Diabetes. Diabetes Care. 2018 04; 41(4):662-663. View in: PubMed

  157. de Boer IH, Bakris G, Cannon CP. Individualizing Blood Pressure Targets for People With Diabetes and Hypertension: Comparing the ADA and the ACC/AHA Recommendations. JAMA. 2018 Apr 03; 319(13):1319-1320. View in: PubMed

  158. Greene SJ, Vaduganathan M, Khan MS, Bakris GL, Weir MR, Seltzer JH, Sattar N, McGuire DK, Januzzi JL, Stockbridge N, Butler J. Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. J Am Coll Cardiol. 2018 03 27; 71(12):1379-1390. View in: PubMed

  159. Al Dhaybi O, Bakris GL. Blood pressure reduced to new guideline goals in patients with high-normal glucose further reduces cardiovascular events. J Clin Hypertens (Greenwich). 2018 04; 20(4):625-626. View in: PubMed

  160. Bakris GL, Zhao L, Kupfer S, Juhasz A, Hisada M, Lloyd E, Oparil S. Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease. J Clin Hypertens (Greenwich). 2018 04; 20(4):694-702. View in: PubMed

  161. Johnson RJ, Bakris GL, Borghi C, Chonchol MB, Feldman D, Lanaspa MA, Merriman TR, Moe OW, Mount DB, Sanchez Lozada LG, Stahl E, Weiner DE, Chertow GM. Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. Am J Kidney Dis. 2018 06; 71(6):851-865. View in: PubMed

  162. Bakris GL, Molitch M. Are All Patients With Type 1 Diabetes Destined for Dialysis if They Live Long Enough? Probably Not. Diabetes Care. 2018 03; 41(3):389-390. View in: PubMed

  163. Laffin LJ, Bakris GL. Results of ACCORDIAN in ACCORD with lower blood pressure begetting lower mortality in patients with diabetes. Diabetes Obes Metab. 2018 06; 20(6):1335-1336. View in: PubMed

  164. Dojki FK, Bakris GL. Blood Pressure Control and Cardiovascular/Renal Outcomes. Endocrinol Metab Clin North Am. 2018 03; 47(1):175-184. View in: PubMed

  165. Heerspink HJL, Andress DL, Bakris G, Brennan JJ, Correa-Rotter R, Dey J, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray J, Perkovic V, Tobe S, Wigderson M, Parving HH, de Zeeuw D. Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes Obes Metab. 2018 06; 20(6):1369-1376. View in: PubMed

  166. Chin MP, Bakris GL, Block GA, Chertow GM, Goldsberry A, Inker LA, Heerspink HJL, O'Grady M, Pergola PE, Wanner C, Warnock DG, Meyer CJ. Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study. Am J Nephrol. 2018; 47(1):40-47. View in: PubMed

  167. Briasoulis A, Al Dhaybi O, Bakris GL. SGLT2 Inhibitors and Mechanisms of Hypertension. Curr Cardiol Rep. 2018 01 19; 20(1):1. View in: PubMed

  168. Bakris G, Sorrentino M. Redefining Hypertension - Assessing the New Blood-Pressure Guidelines. N Engl J Med. 2018 02 08; 378(6):497-499. View in: PubMed

  169. Garlo KG, White WB, Bakris GL, Zannad F, Wilson CA, Kupfer S, Vaduganathan M, Morrow DA, Cannon CP, Charytan DM. Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes. Clin J Am Soc Nephrol. 2018 03 07; 13(3):398-405. View in: PubMed

  170. Cushman WC, Bakris GL, White WB, Weber MA, Sica D, Roberts A, Lloyd E, Kupfer S. A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension. J Hypertens. 2018 04; 36(4):947-956. View in: PubMed

  171. Plutzky J, Bakris G. Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease: Turning the Page. Circulation. 2018 01 09; 137(2):130-133. View in: PubMed

  172. Brook RD, Kaciroti N, Bakris G, Dahlöf B, Pitt B, Velazquez E, Weber M, Zappe DH, Hau T, Jamerson KA. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients. J Am Heart Assoc. 2018 01 04; 7(1). View in: PubMed

  173. Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Xie J, Zhang H, Zinman B, Desai M, Perkovic V. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. Am J Nephrol. 2017 Dec 13; 46(6):462-472. View in: PubMed

  174. Riley DJ, Weir M, Bakris GL. Renal adaptation to the failing heart. Postgrad Med. 1994 Jun; 95(8):153-156. View in: PubMed

  175. Riley DJ, Weir M, Bakris GL. Renal adaptation to the failing heart. Postgrad Med. 1994 Jun; 95(8):141-150. View in: PubMed

  176. Bakris GL, Talbert R. Drug dosing in patients with renal insufficiency. Postgrad Med. 1993 Dec; 94(8):153-164. View in: PubMed

  177. Weir MR, Bushinsky DA, Benton WW, Woods SD, Mayo MR, Arthur SP, Pitt B, Bakris GL. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors. Am J Med. 2018 05; 131(5):555-564.e3. View in: PubMed

  178. Al Dhabyi O, Bakris GL. Initial Single-Pill Blood Pressure-Lowering Therapy: Should It Be for Most People? J Am Heart Assoc. 2017 11 18; 6(11). View in: PubMed

  179. Yamout H, Bakris GL. Consequences of Overinterpreting Serum Creatinine Increases when Achieving BP Reduction: Balancing Risks and Benefits of BP Reduction in Hypertension. Clin J Am Soc Nephrol. 2018 01 06; 13(1):9-10. View in: PubMed

  180. Deedwania P, Weber M, Reimitz PE, Bakris G. Olmesartan-based monotherapy vs combination therapy in hypertension: A meta-analysis based on age and chronic kidney disease status. J Clin Hypertens (Greenwich). 2017 Dec; 19(12):1309-1318. View in: PubMed

  181. Hwang YC, Morrow DA, Cannon CP, Liu Y, Bergenstal R, Heller S, Mehta C, Cushman W, Bakris GL, Zannad F, White WB. High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial. Diabetes Obes Metab. 2018 03; 20(3):654-659. View in: PubMed

  182. Omboni S, Kario K, Bakris G, Parati G. Effect of antihypertensive treatment on 24-h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies based on olmesartan mono or combination treatment. J Hypertens. 2018 04; 36(4):720-733. View in: PubMed

  183. Bakris GL. MY APPROACH to the elderly patient with resistant hypertension. Trends Cardiovasc Med. 2018 01; 28(1):79-80. View in: PubMed

  184. Waksman R, Bakris GL, Steinvil A, Garcia-Garcia H, Brown AL, DiFilippo W, Scott T, Singh J, DeBruin V, Jones D, Jolivette D, Bhatt DL. High screen failure rate in patients with resistant hypertension: Findings from SYMPLICITY HTN-3. Am Heart J. 2017 Oct; 192:76-84. View in: PubMed

  185. de Boer IH, Bangalore S, Benetos A, Davis AM, Michos ED, Muntner P, Rossing P, Zoungas S, Bakris G. Diabetes and Hypertension: A Position Statement by the American Diabetes Association. Diabetes Care. 2017 09; 40(9):1273-1284. View in: PubMed

  186. Dojki FK, Bakris G. Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease. Curr Opin Nephrol Hypertens. 2017 09; 26(5):368-374. View in: PubMed

  187. Laffin LJ, Jafar MS, Bakris GL. Severe menses-associated hypertension successfully treated with gonadotropin-releasing hormone agonist. J Clin Hypertens (Greenwich). 2017 Nov; 19(11):1202-1203. View in: PubMed

  188. Ai Dhaybi O, Bakris GL. Renal Targeted Therapies of Antihypertensive and Cardiovascular Drugs for Patients With Stages 3 Through 5d Kidney Disease. Clin Pharmacol Ther. 2017 Sep; 102(3):450-458. View in: PubMed

  189. Johnson W, White WB, Sica D, Bakris GL, Weber MA, Handley A, Perez A, Cao C, Kupfer S, Saunders EB. Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension. J Clin Hypertens (Greenwich). 2017 Jul; 19(7):695-701. View in: PubMed

  190. Ku E, Bakris G, Johansen KL, Lin F, Sarnak MJ, Campese VM, Jamerson K, Gassman JJ, Smogorzewski M, Hsu CY. Acute Declines in Renal Function during Intensive BP Lowering: Implications for Future ESRD Risk. J Am Soc Nephrol. 2017 Sep; 28(9):2794-2801. View in: PubMed

  191. Kario K, Bhatt DL, Brar S, Bakris GL. Differences in Dynamic Diurnal Blood Pressure Variability Between Japanese and American Treatment-Resistant Hypertensive Populations. Circ J. 2017 Aug 25; 81(9):1337-1345. View in: PubMed

  192. de Leeuw PW, Bisognano JD, Bakris GL, Nadim MK, Haller H, Kroon AA. Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy: Results of the 6-Year Open Follow-Up. Hypertension. 2017 May; 69(5):836-843. View in: PubMed

  193. Sternlicht H, Bakris GL. Resistant Hypertension: A Refractory Disease or Refractory Patient. Hypertension. 2017 04; 69(4):582-583. View in: PubMed

  194. Cavender MA, White WB, Jarolim P, Bakris GL, Cushman WC, Kupfer S, Gao Q, Mehta CR, Zannad F, Cannon CP, Morrow DA. Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care). Circulation. 2017 May 16; 135(20):1911-1921. View in: PubMed

  195. Bakris G. Response by Bakris to Letter Regarding Article, "The Implications of Blood Pressure Measurement Methods on Treatment Targets for Blood Pressure". Circulation. 2017 02 14; 135(7):e47. View in: PubMed

  196. Mahfoud F, Bakris G, Bhatt DL, Esler M, Ewen S, Fahy M, Kandzari D, Kario K, Mancia G, Weber M, Böhm M. Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry. Eur Heart J. 2017 01 07; 38(2):93-100. View in: PubMed

  197. Bakris G, Briasoulis A. Searching for the Optimal Blood Pressure Range in the Elderly: Are We There Yet? J Am Coll Cardiol. 2017 02 07; 69(5):494-496. View in: PubMed

  198. Blacher J, Levy BI, Mourad JJ, Safar ME, Bakris G. Hypertension control and cardiovascular disease - Authors' reply. Lancet. 2017 01 14; 389(10065):154-155. View in: PubMed

  199. Griffin KA, Picken MM, Bakris G, Bidani AK. Relative antihypertensive and glomeruloprotective efficacies of enalapril and candesartan cilexetil in the remnant kidney model. J Renin Angiotensin Aldosterone Syst. 2001 Mar; 2(1_suppl):S191-S195. View in: PubMed

  200. Wachter R, Halbach M, Bakris GL, Bisognano JD, Haller H, Beige J, Kroon AA, Nadim MK, Lovett EG, Schafer JE, de Leeuw PW. An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems. J Am Soc Hypertens. 2017 02; 11(2):81-91. View in: PubMed

  201. Heller SR, Bergenstal RM, White WB, Kupfer S, Bakris GL, Cushman WC, Mehta CR, Nissen SE, Wilson CA, Zannad F, Liu Y, Gourlie NM, Cannon CP. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial. Diabetes Obes Metab. 2017 05; 19(5):664-671. View in: PubMed

  202. Yano Y, Rakugi H, Bakris GL, Lloyd-Jones DM, Oparil S, Saruta T, Shimada K, Matsuoka H, Imai Y, Ogihara T. On-Treatment Blood Pressure and Cardiovascular Outcomes in Older Adults With Isolated Systolic Hypertension. Hypertension. 2017 02; 69(2):220-227. View in: PubMed

  203. Cefalu WT, Boulton AJ, Tamborlane WV, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Kahn SE, Weinger K, Blonde L, de Groot M, Rich S, D'Alessio D, Reynolds L, Riddle MC. Diabetes Care: "Taking It to the Limit One More Time". Diabetes Care. 2017 01; 40(1):3-6. View in: PubMed

  204. Skyler JS, Bakris GL, Bonifacio E, Darsow T, Eckel RH, Groop L, Groop PH, Handelsman Y, Insel RA, Mathieu C, McElvaine AT, Palmer JP, Pugliese A, Schatz DA, Sosenko JM, Wilding JP, Ratner RE. Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes. 2017 02; 66(2):241-255. View in: PubMed

  205. Sternlicht H, Bakris GL. The Kidney in Hypertension. Med Clin North Am. 2017 Jan; 101(1):207-217. View in: PubMed

  206. Rossignol P, Girerd N, Bakris G, Vardeny O, Claggett B, McMurray JJV, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Spanyers S, Vincent J, Fay R, Lamiral Z, Solomon SD, Zannad F, Pitt B. Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. Eur J Heart Fail. 2017 06; 19(6):792-799. View in: PubMed

  207. Laffin LJ, Bakris GL. Catheter-Based Renal Denervation for Resistant Hypertension: Will It Ever Be Ready for "Prime Time"? Am J Hypertens. 2017 Sep 01; 30(9):841-846. View in: PubMed

  208. Pocock SJ, Bakris G, Bhatt DL, Brar S, Fahy M, Gersh BJ. Regression to the Mean in SYMPLICITY HTN-3: Implications for Design and Reporting of Future Trials. J Am Coll Cardiol. 2016 11 01; 68(18):2016-2025. View in: PubMed

  209. Kraus MA, Kansal S, Copland M, Komenda P, Weinhandl ED, Bakris GL, Chan CT, Fluck RJ, Burkart JM. Intensive Hemodialysis and Potential Risks With Increasing Treatment. Am J Kidney Dis. 2016 Nov; 68(5S1):S51-S58. View in: PubMed

  210. McCullough PA, Chan CT, Weinhandl ED, Burkart JM, Bakris GL. Intensive Hemodialysis, Left Ventricular Hypertrophy, and Cardiovascular Disease. Am J Kidney Dis. 2016 Nov; 68(5S1):S5-S14. View in: PubMed

  211. Bakris GL, Burkart JM, Weinhandl ED, McCullough PA, Kraus MA. Intensive Hemodialysis, Blood Pressure, and Antihypertensive Medication Use. Am J Kidney Dis. 2016 Nov; 68(5S1):S15-S23. View in: PubMed

  212. Eskander MF, Bliss LA, McCarthy EP, de Geus SW, Chau Ng S, Nagle D, Rodrigue JR, Tseng JF. 35th Annual Meeting of the European Association for the Study of Diabetes : Brussels, Belgium, 28 September-2 October 1999. Diabetologia. 1999 Aug; 42(Suppl 1):A1-A330. View in: PubMed

  213. Eskander MF, Bliss LA, McCarthy EP, de Geus SW, Chau Ng S, Nagle D, Rodrigue JR, Tseng JF. Massachusetts Healthcare Reform and Trends in Emergent Colon Resection. Dis Colon Rectum. 2016 Nov; 59(11):1063-1072. View in: PubMed

  214. Eskander MF, Bliss LA, McCarthy EP, de Geus SW, Chau Ng S, Nagle D, Rodrigue JR, Tseng JF. Massachusetts Healthcare Reform and Trends in Emergent Colon Resection. Dis Colon Rectum. 2016 Nov; 59(11):1063-1072. View in: PubMed

  215. Eskander MF, Bliss LA, McCarthy EP, de Geus SW, Chau Ng S, Nagle D, Rodrigue JR, Tseng JF. Massachusetts Healthcare Reform and Trends in Emergent Colon Resection. Dis Colon Rectum. 2016 Nov; 59(11):1063-1072. View in: PubMed

  216. Eskander MF, Bliss LA, McCarthy EP, de Geus SW, Chau Ng S, Nagle D, Rodrigue JR, Tseng JF. Massachusetts Healthcare Reform and Trends in Emergent Colon Resection. Dis Colon Rectum. 2016 Nov; 59(11):1063-1072. View in: PubMed

  217. Dhaybi OA, Bakris G. Mineralocorticoid antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens. 2017 01; 26(1):50-55. View in: PubMed

  218. Cornel JH, Bakris GL, Stevens SR, Alvarsson M, Bax WA, Chuang LM, Engel SS, Lopes RD, McGuire DK, Riefflin A, Rodbard HW, Sinay I, Tankova T, Wainstein J, Peterson ED, Holman RR. Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. Diabetes Care. 2016 Dec; 39(12):2304-2310. View in: PubMed

  219. Dojki FK, Bakris G. Diabetes: Blood pressure goals in T2DM - time for a rethink? Nat Rev Endocrinol. 2016 11; 12(11):629-630. View in: PubMed

  220. Weber MA, Bakris GL, White WB, Xie L, Bharucha D, Patel M. The Effects of Nebivolol-Valsartan Single-Pill Combinations in Reducing Blood Pressure in Patients with Stage I or II Hypertension. J Am Soc Hypertens. 2016 07; 10 Suppl 1:e8. View in: PubMed

  221. Ruilope LM, Nowack C, Bakris GL. Masked and Nocturnal Hypertension in the ARTS-DN ABPM Sub-Study with Finerenone. J Am Soc Hypertens. 2016 07; 10 Suppl 1:e7. View in: PubMed

  222. Cefalu WT, Boulton AJ, Tamborlane WV, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Weinger K, Blonde L, de Groot M, Rich SS, D'Alessio D, Riddle MC, Reynolds L. Diabetes Care: "Lagniappe" and "Seeing Is Believing"! Diabetes Care. 2016 07; 39(7):1069-71. View in: PubMed

  223. Briasoulis A, Bakris GL. Current Status of Renal Denervation in Hypertension. Curr Cardiol Rep. 2016 11; 18(11):107. View in: PubMed

  224. Cefalu WT, Boulton AJ, Tamborlane WV, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Weinger K, Blonde L, de Groot M, Riddle MC, Hill Golden S, Rich SS, D'Alessio D, Reynolds L. Building Momentum: Taking on the Real “Issues” of Diabetes Care! Diabetes Care. 2016 Jan; 39(1):10-12. View in: PubMed

  225. Bakris GL. The Implications of Blood Pressure Measurement Methods on Treatment Targets for Blood Pressure. Circulation. 2016 09 27; 134(13):904-5. View in: PubMed

  226. Al Dhaybi O, Bakris G. New Onset Hypertension Linked to Generic Cyclosporine Substitution in Post-Renal Transplant Patient. Am J Nephrol. 2016; 44(3):219-23. View in: PubMed

  227. Ku E, Gassman J, Appel LJ, Smogorzewski M, Sarnak MJ, Glidden DV, Bakris G, Gutiérrez OM, Hebert LA, Ix JH, Lea J, Lipkowitz MS, Norris K, Ploth D, Pogue VA, Rostand SG, Siew ED, Sika M, Tisher CC, Toto R, Wright JT, Wyatt C, Hsu CY. BP Control and Long-Term Risk of ESRD and Mortality. J Am Soc Nephrol. 2017 02; 28(2):671-677. View in: PubMed

  228. White WB, Wilson CA, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Heller SK, Mehta CR, Nissen SE, Zannad F, Kupfer S. Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. Hypertension. 2016 09; 68(3):606-13. View in: PubMed

  229. Yamout H, Bakris GL. Diabetic nephropathy: SGLT2 inhibitors might halt progression of diabetic nephropathy. Nat Rev Nephrol. 2016 10; 12(10):583-4. View in: PubMed

  230. Zannad F, Stough WG, Lipicky RJ, Tamargo J, Bakris GL, Borer JS, Alonso García Mde L, Hadjadj S, Koenig W, Kupfer S, McCullough PA, Mosenzon O, Pocock S, Scheen AJ, Sourij H, Van der Schueren B, Stahre C, White WB, Calvo G. Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. Eur Heart J Cardiovasc Pharmacother. 2016 07; 2(3):200-5. View in: PubMed

  231. Weir MR, Bakris GL, Gross C, Mayo MR, Garza D, Stasiv Y, Yuan J, Berman L, Williams GH. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Kidney Int. 2016 09; 90(3):696-704. View in: PubMed

  232. Bakris GL, Molitch ME. Should Restrictions Be Relaxed for Metformin Use in Chronic Kidney Disease? Yes, They Should Be Relaxed! What's the Fuss? Diabetes Care. 2016 Jul; 39(7):1287-91. View in: PubMed

  233. White WB, Kupfer S, Zannad F, Mehta CR, Wilson CA, Lei L, Bakris GL, Nissen SE, Cushman WC, Heller SR, Bergenstal RM, Fleck PR, Cannon CP. Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial. Diabetes Care. 2016 Jul; 39(7):1267-73. View in: PubMed

  234. Laffin LJ, Majewski C, Liao C, Bakris GL. Relationship Between Obesity, Hypertension, and Aldosterone Production in Postmenopausal African American Women: A Pilot Study. J Clin Hypertens (Greenwich). 2016 12; 18(12):1216-1221. View in: PubMed

  235. Bakris GL. Current and future potassium binders. Nephrol News Issues. 2016 Apr; 30(4):suppl 27-31. View in: PubMed

  236. Laffin LJ, Bakris GL. Renal Denervation: a Field in Flux. Curr Hypertens Rep. 2016 Jul; 18(7):56. View in: PubMed

  237. Kantor GR, Lobl JK, Bakris GL. The Medical Bookshelf. Postgrad Med. 1993 Jan; 93(1):14. View in: PubMed

  238. Shimada YJ, Cannon CP, Liu Y, Wilson C, Kupfer S, Menon V, Cushman WC, Mehta CR, Bakris GL, Zannad F, White WB. Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial. Am Heart J. 2016 May; 175:18-27. View in: PubMed

  239. Zannad F, Rossignol P, Stough WG, Epstein M, Alonso Garcia Mde L, Bakris GL, Butler J, Kosiborod M, Berman L, Mebazaa A, Rasmussen HS, Ruilope LM, Stockbridge N, Thompson A, Wittes J, Pitt B. New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval. Int J Cardiol. 2016 Aug 01; 216:46-51. View in: PubMed

  240. Kario K, Bhatt DL, Kandzari DE, Brar S, Flack JM, Gilbert C, Oparil S, Robbins M, Townsend RR, Bakris G. Impact of Renal Denervation on Patients With Obstructive Sleep Apnea and Resistant Hypertension - Insights From the SYMPLICITY HTN-3 Trial. Circ J. 2016 May 25; 80(6):1404-12. View in: PubMed

  241. Weber MA, Bloch M, Bakris GL, Weir MR, Zappe DH, Dahlof B, Velazquez EJ, Pitt B, Basile JN, Jamerson K, Hua TA. Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. J Clin Hypertens (Greenwich). 2016 Apr; 18(4):299-307. View in: PubMed

  242. Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB, Bakris G, Perez A, Smith SR. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. JAMA. 2016 Mar 08; 315(10):990-1004. View in: PubMed

  243. Majewski C, Bakris GL. Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy? Curr Diab Rep. 2016 Apr; 16(4):24. View in: PubMed

  244. Blacher J, Levy BI, Mourad JJ, Safar ME, Bakris G. From epidemiological transition to modern cardiovascular epidemiology: hypertension in the 21st century. Lancet. 2016 Jul 30; 388(10043):530-2. View in: PubMed

  245. Sternlicht H, Bakris GL. Hydrochlorothiazide as the Diuretic of Choice for Hypertension: Time to Kick the Habit. J Am Coll Cardiol. 2016 Feb 02; 67(4):390-391. View in: PubMed

  246. Bakris GL, Nowack C. Finerenone for Albuminuria in Patients With Diabetic Nephropathy--Reply. JAMA. 2016 Jan 19; 315(3):306. View in: PubMed

  247. White WB, Cuadra RH, Lloyd E, Bakris GL, Kupfer S. Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. J Hypertens. 2016 Apr; 34(4):788-97. View in: PubMed

  248. Sternlicht H, Bakris GL. Management of Hypertension in Diabetic Nephropathy: How Low Should We Go? Blood Purif. 2016; 41(1-3):139-43. View in: PubMed

  249. Sternlicht H, Bakris GL. Hypertension: SGLT2 inhibitors: not just another glucose-lowering agent. Nat Rev Nephrol. 2016 Mar; 12(3):128-9. View in: PubMed

  250. Kario K, Bhatt DL, Brar S, Cohen SA, Fahy M, Bakris GL. Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension. 2015 Dec; 66(6):1130-7. View in: PubMed

  251. Yeh JS, Bakris GL, Taler SJ. CLINICAL DECISIONS. Blood-Pressure Control. N Engl J Med. 2015 Nov 26; 373(22):2180-2. View in: PubMed

  252. Rossignol P, Massy ZA, Azizi M, Bakris G, Ritz E, Covic A, Goldsmith D, Heine GH, Jager KJ, Kanbay M, Mallamaci F, Ortiz A, Vanholder R, Wiecek A, Zoccali C, London GM, Stengel B, Fouque D. The double challenge of resistant hypertension and chronic kidney disease. Lancet. 2015 Oct 17; 386(10003):1588-98. View in: PubMed

  253. Puri R, Nissen SE, Menon V, Shao M, Hsu A, Bakris GL, Kastelein JJ, Williams B, Armbrecht J, Brunel P, Kataoka Y, Nicholls SJ. Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS. Atherosclerosis. 2015 Dec; 243(2):553-9. View in: PubMed

  254. Pitt B, Bakris GL, Bushinsky DA, Garza D, Mayo MR, Stasiv Y, Christ-Schmidt H, Berman L, Weir MR. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail. 2015 Oct; 17(10):1057-65. View in: PubMed

  255. Sternlicht H, Bakris GL. Spironolactone for resistant hypertension--hard to resist? Lancet. 2015 Nov 21; 386(10008):2032-2034. View in: PubMed

  256. Bushinsky DA, Williams GH, Pitt B, Weir MR, Freeman MW, Garza D, Stasiv Y, Li E, Berman L, Bakris GL. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. Kidney Int. 2015 Dec; 88(6):1427-1433. View in: PubMed

  257. Giles TD, Bakris G, Oparil S, Weber MA, Li H, Mallick M, Bharucha DB, Chen C, Ferguson WG. Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension. J Am Soc Hypertens. 2015 Nov; 9(11):845-54. View in: PubMed

  258. Flack JM, Bhatt DL, Kandzari DE, Brown D, Brar S, Choi JW, D'Agostino R, East C, Katzen BT, Lee L, Leon MB, Mauri L, O'Neill WW, Oparil S, Rocha-Singh K, Townsend RR, Bakris G. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. J Am Soc Hypertens. 2015 Oct; 9(10):769-779. View in: PubMed

  259. Sarafidis PA, Georgianos PI, Bakris GL. Advances in treatment of hyperkalemia in chronic kidney disease. Expert Opin Pharmacother. 2015; 16(14):2205-15. View in: PubMed

  260. Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015 Sep 01; 314(9):884-94. View in: PubMed

  261. Cefalu WT, Boulton AJ, Boulton AJ, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Weinger K, Blonde L, de Groot M, Riddle MC, Henry R, Golden SH, Rich S, Reynolds L. Status of Diabetes Care: New Challenges, New Concepts, New Measures--Focusing on the Future! Diabetes Care. 2015 Jul; 38(7):1177-80. View in: PubMed

  262. Pitt B, Bakris GL. New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future. Hypertension. 2015 Oct; 66(4):731-8. View in: PubMed

  263. Patney V, Whaley-Connell A, Bakris G. Hypertension Management in Diabetic Kidney Disease. Diabetes Spectr. 2015 Aug; 28(3):175-80. View in: PubMed

  264. Iliescu R, Lohmeier TE, Tudorancea I, Laffin L, Bakris GL. Renal denervation for the treatment of resistant hypertension: review and clinical perspective. Am J Physiol Renal Physiol. 2015 Oct 01; 309(7):F583-94. View in: PubMed

  265. Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial. JAMA. 2015 Jul 14; 314(2):151-61. View in: PubMed

  266. Bakris G. Summary and Conclusions. High Blood Press Cardiovasc Prev. 2015 Jul; 22 Suppl 1:S23. View in: PubMed

  267. Kario K, Bakris GL, Bhatt D. 4A.10: PREFERENTIAL REDUCTION IN MORNING/NOCTURNAL HYPERTENSION BY RENAL DENERVATION FOR DRUG- RESISTANT HYPERTENSION: A NEW ABPM ANALYSIS OF SYMPLICITY HTN-3 AND HTN-JAPAN. J Hypertens. 2015 Jun; 33 Suppl 1:e52. View in: PubMed

  268. de Leeuw PW, Bakris GL, Nadim MK, Haller H, Lovett EG, Bisognano JD. 8B.06: BAROREFLEX ACTIVATION THERAPY CONSISTENTLY MAINTAINS BLOOD PRESSURE REDUCTION IN A LARGE RESISTANT HYPERTENSION COHORT FOR AT LEAST 6 YEARS. J Hypertens. 2015 Jun; 33 Suppl 1:e108. View in: PubMed

  269. Laffin LJ, Bakris GL. Endothelin antagonism and hypertension: an evolving target. Semin Nephrol. 2015 Mar; 35(2):168-75. View in: PubMed

  270. Laffin LJ, Bakris GL. Update on blood pressure goals in diabetes mellitus. Curr Cardiol Rep. 2015 Jun; 17(6):37. View in: PubMed

  271. McMullan CJ, Yano Y, Bakris GL, Kario K, Phillips RA, Forman JP. Racial impact of diurnal variations in blood pressure on cardiovascular events in chronic kidney disease. J Am Soc Hypertens. 2015 Apr; 9(4):299-306. View in: PubMed

  272. Weir MR, Bakris GL, Pitt B. New agents for hyperkalemia. N Engl J Med. 2015 04 16; 372(16):1570-1. View in: PubMed

  273. Briasoulis A, Bakris GL. A clinician's perspective of the role of renal sympathetic nerves in hypertension. Front Physiol. 2015; 6:75. View in: PubMed

  274. Glassock RJ, Bakris GL. Hypertension: Impact of blood pressure lowering in type 2 diabetes. Nat Rev Nephrol. 2015 Jun; 11(6):320-1. View in: PubMed

  275. Bakris GL, Townsend RR, Flack JM, Brar S, Cohen SA, D'Agostino R, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O'Neill WW, Oparil S, Rocha-Singh K, Bhatt DL. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. J Am Coll Cardiol. 2015 Apr 07; 65(13):1314-1321. View in: PubMed

  276. Briasoulis A, Bakris G. Renal Denervation After SYMPLICITY HTN-3: Where Do We Go? Can J Cardiol. 2015 May; 31(5):642-8. View in: PubMed

  277. Elliott WJ, Whitmore J, Feldstein JD, Bakris GL. Efficacy and safety of perindopril arginine + amlodipine in hypertension. J Am Soc Hypertens. 2015 Apr; 9(4):266-74. View in: PubMed

  278. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Lam H, White WB. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015 May 23; 385(9982):2067-76. View in: PubMed

  279. Bakris GL, Bhatt DL. Reply: A mechanistic explanation for the minimal impact of renal denervation on 24-h ambulatory blood pressure in SIMPLICITY HTN-3. J Am Coll Cardiol. 2015 Mar 10; 65(9):959-60. View in: PubMed

  280. Majewski C, Bakris GL. Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes. Diabetes Care. 2015 Mar; 38(3):429-30. View in: PubMed

  281. Laffin LJ, Bakris GL. Renal denervation for resistant hypertension and beyond. Adv Chronic Kidney Dis. 2015 Mar; 22(2):133-9. View in: PubMed

  282. Ruilope LM, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Ferreira AC, Pieper A, Kimmeskamp-Kirschbaum N, Bakris GL. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Am J Nephrol. 2014; 40(6):572-81. View in: PubMed

  283. Laffin LJ, Bakris GL. Hypertension and new treatment approaches targeting the sympathetic nervous system. Curr Opin Pharmacol. 2015 Apr; 21:20-4. View in: PubMed

  284. Sarafidis PA, Bakris GL. Cardiovascular disease in CKD in 2014: new insights into cardiovascular risk factors and outcomes. Nat Rev Nephrol. 2015 Feb; 11(2):70-2. View in: PubMed

  285. Böhm M, Schumacher H, Schmieder RE, Mann JF, Teo K, Lonn E, Sleight P, Mancia G, Linz D, Mahfoud F, Ukena C, Sliwa K, Bakris G, Yusuf S. Resting heart rate is associated with renal disease outcomes in patients with vascular disease: results of the ONTARGET and TRANSCEND studies. J Intern Med. 2015 Jul; 278(1):38-49. View in: PubMed

  286. White WB, Turner JR, Sica DA, Bisognano JD, Calhoun DA, Townsend RR, Aronow HD, Bhatt DL, Bakris GL. Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013. J Am Soc Hypertens. 2014 Oct; 8(10):743-57. View in: PubMed

  287. Oliva RV, Bakris GL. Sympathetic activation in resistant hypertension: theory and therapy. Semin Nephrol. 2014; 34(5):550-9. View in: PubMed

  288. Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015 Jan 15; 372(3):211-21. View in: PubMed

  289. Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, Flack JM, Katzen BT, Lea J, Lee DP, Leon MB, Ma A, Massaro J, Mauri L, Oparil S, O'Neill WW, Patel MR, Rocha-Singh K, Sobotka PA, Svetkey L, Townsend RR, Bakris GL. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015 Jan 21; 36(4):219-27. View in: PubMed

  290. Zannad F, Stough WG, Mahfoud F, Bakris GL, Kjeldsen SE, Kieval RS, Haller H, Yared N, De Ferrari GM, Piña IL, Stein K, Azizi M. Design considerations for clinical trials of autonomic modulation therapies targeting hypertension and heart failure. Hypertension. 2015 Jan; 65(1):5-15. View in: PubMed

  291. Chin MP, Wrolstad D, Bakris GL, Chertow GM, de Zeeuw D, Goldsberry A, Linde PG, McCullough PA, McMurray JJ, Wittes J, Meyer CJ. Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. J Card Fail. 2014 Dec; 20(12):953-8. View in: PubMed

  292. Nathan S, Bakris GL. The future of renal denervation in resistant hypertension. Curr Hypertens Rep. 2014 Dec; 16(12):494. View in: PubMed

  293. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley-Connell AT, Molitch ME. Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis. 2014 Oct; 64(4):510-33. View in: PubMed

  294. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley-Connell AT, Molitch ME. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014 Oct; 37(10):2864-83. View in: PubMed

  295. Cefalu WT, Boulton AJ, Tamborlane WV, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Weinger K, Blonde L, de Groot M, Riddle MC, Henry RR, Hill Golden S, Rich S, Reynolds L. Status of Diabetes Care: "It just doesn't get any better . . . or does it?". Diabetes Care. 2014 Jul; 37(7):1782-5. View in: PubMed

  296. Yamout H, Bakris GL. In search for the 'sweet spot' for blood pressure level in diabetes. Heart. 2014 Sep 15; 100(18):1404-5. View in: PubMed

  297. Yamout H, Perkovic V, Davies M, Woo V, de Zeeuw D, Mayer C, Vijapurkar U, Kline I, Usiskin K, Meininger G, Bakris G. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol. 2014; 40(1):64-74. View in: PubMed

  298. Lazich I, Bakris GL. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol. 2014 May; 34(3):333-9. View in: PubMed

  299. Bakris GL. The role of aldosterone in the spectrum of cardiovascular and kidney disease risk: introduction. Semin Nephrol. 2014 May; 34(3):245-6. View in: PubMed

  300. Bhatt DL, Bakris GL. Renal denervation for resistant hypertension. N Engl J Med. 2014 07 10; 371(2):184. View in: PubMed

  301. Yale JF, Bakris G, Cariou B, Nieto J, David-Neto E, Yue D, Wajs E, Figueroa K, Jiang J, Law G, Usiskin K, Meininger G. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014 Oct; 16(10):1016-27. View in: PubMed

  302. Chin MP, Reisman SA, Bakris GL, O'Grady M, Linde PG, McCullough PA, Packham D, Vaziri ND, Ward KW, Warnock DG, Meyer CJ. Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. Am J Nephrol. 2014; 39(6):499-508. View in: PubMed

  303. Vemulapalli S, Ard J, Bakris GL, Bhatt DL, Brown AS, Cushman WC, Ferdinand KC, Flack JM, Fleg JL, Katzen BT, Kostis JB, Oparil S, Patel CB, Pepine CJ, Piña IL, Rocha-Singh KJ, Townsend RR, Peterson ED, Califf RM, Patel MR. Proceedings from Duke resistant hypertension think tank. Am Heart J. 2014 Jun; 167(6):775-88.e1. View in: PubMed

  304. Bakris GL, Townsend RR, Liu M, Cohen SA, D'Agostino R, Flack JM, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O'Neill WW, Oparil S, Rocha-Singh K, Bhatt DL. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J Am Coll Cardiol. 2014 Sep 16; 64(11):1071-8. View in: PubMed

  305. Yamout H, Lazich I, Bakris GL. Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease. Adv Chronic Kidney Dis. 2014 May; 21(3):281-6. View in: PubMed

  306. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014 Apr 10; 370(15):1393-401. View in: PubMed

  307. Karovic S, Wen Y, Karrison TG, Bakris GL, Levine MR, House LK, Wu K, Thomeas V, Rudek MA, Wright JJ, Cohen EE, Fleming GF, Ratain MJ, Maitland ML. Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. Clin Pharmacol Ther. 2014 Jul; 96(1):27-35. View in: PubMed

  308. Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014 May; 8(5):330-9. View in: PubMed

  309. Briasoulis A, Silver A, Yano Y, Bakris GL. Orthostatic hypotension associated with baroreceptor dysfunction: treatment approaches. J Clin Hypertens (Greenwich). 2014 Feb; 16(2):141-8. View in: PubMed

  310. Bakris GL, Molitch M. Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care. 2014; 37(3):867-75. View in: PubMed

  311. Sarafidis PA, Bakris GL. Renin inhibition in patients with chronic kidney disease: is it conclusively non-indicated? J Renin Angiotensin Aldosterone Syst. 2014 Mar; 15(1):97-8. View in: PubMed

  312. Sarafidis PA, Bakris GL. Early patterns of blood pressure change and future coronary atherosclerosis. JAMA. 2014 Feb 05; 311(5):471-2. View in: PubMed

  313. Byrd JB, Bakris G, Jamerson K. The contribution of the ACCOMPLISH trial to the treatment of stage 2 hypertension. Curr Hypertens Rep. 2014 Mar; 16(3):419. View in: PubMed

  314. Weber MA, White WB, Sica D, Bakris GL, Cao C, Roberts A, Kupfer S. Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension. Blood Press Monit. 2014 Apr; 19(2):90-7. View in: PubMed

  315. Socolovsky C, Masi C, Hamlish T, Aduana G, Arora S, Bakris G, Johnson D. Evaluating the role of key learning theories in ECHO: a telehealth educational program for primary care providers. Prog Community Health Partnersh. 2013; 7(4):361-8. View in: PubMed

  316. Yano Y, Bakris GL, Inokuchi T, Ohba Y, Tamaki N, Nagata M, Kuwabara M, Yokota N, Eto T, Kuroki M, Shimada K, Kario K. Association of cognitive dysfunction with cardiovascular disease events in elderly hypertensive patients. J Hypertens. 2014 Feb; 32(2):423-31. View in: PubMed

  317. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, Flack JM, Carter BL, Materson BJ, Ram CV, Cohen DL, Cadet JC, Jean-Charles RR, Taler S, Kountz D, Townsend RR, Chalmers J, Ramirez AJ, Bakris GL, Wang J, Schutte AE, Bisognano JD, Touyz RM, Sica D, Harrap SB. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014 Jan; 16(1):14-26. View in: PubMed

  318. Yamout H, Bakris GL. Evidence-based triple antihypertensive therapy yields lower mortality in older patients with diabetes mellitus. Hypertension. 2014 Feb; 63(2):220-1. View in: PubMed

  319. Bakris G, Nathan S. Renal denervation and left ventricular mass regression: a benefit beyond blood pressure reduction? J Am Coll Cardiol. 2014 May 13; 63(18):1924-5. View in: PubMed

  320. Bakris G, Sarafidis P, Agarwal R, Ruilope L. Review of blood pressure control rates and outcomes. J Am Soc Hypertens. 2014 Feb; 8(2):127-41. View in: PubMed

  321. Smith SM, Gong Y, Handberg E, Messerli FH, Bakris GL, Ahmed A, Bavry AA, Pepine CJ, Cooper-Dehoff RM. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens. 2014 Mar; 32(3):635-43. View in: PubMed

  322. Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Messig M, Vincent J, Girerd N, Bakris G, Pitt B, Zannad F. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail. 2014 Jan; 7(1):51-8. View in: PubMed

  323. Thomas CC, Bakris G. Metformin nephrotoxicity insights: will they change clinical management? J Diabetes. 2014 Mar; 6(2):111-2. View in: PubMed

  324. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, Flack JM, Carter BL, Materson BJ, Ram CV, Cohen DL, Cadet JC, Jean-Charles RR, Taler S, Kountz D, Townsend R, Chalmers J, Ramirez AJ, Bakris GL, Wang J, Schutte AE, Bisognano JD, Touyz RM, Sica D, Harrap SB. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014 Jan; 32(1):3-15. View in: PubMed

  325. Bakris GL, Doghramji PP, Keenan RT, Silber SH. CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts. Am J Med. 2014 Jan; 127(1):S1. View in: PubMed

  326. Tsioufis C, Kasiakogias A, Kordalis A, Dimitriadis K, Thomopoulos C, Tsiachris D, Vasileiou P, Doumas M, Makris T, Papademetriou V, Kallikazaros I, Bakris G, Stefanadis C. Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study. J Hypertens. 2014 Feb; 32(2):415-22. View in: PubMed

  327. de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, Chertow GM. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013 12 26; 369(26):2492-503. View in: PubMed

  328. Lambers Heerspink HJ, Chertow GM, Akizawa T, Audhya P, Bakris GL, Goldsberry A, Krauth M, Linde P, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Christ-Schmidt H, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, de Zeeuw D. Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. Nephrol Dial Transplant. 2013 Nov; 28(11):2841-50. View in: PubMed

  329. Yano Y, Briasoulis A, Bakris GL, Hoshide S, Wang JG, Shimada K, Kario K. Effects of antihypertensive treatment in Asian populations: a meta-analysis of prospective randomized controlled studies (CARdiovascular protectioN group in Asia: CARNA). J Am Soc Hypertens. 2014 Feb; 8(2):103-16. View in: PubMed

  330. Bakris G. Chronic kidney disease: optimal blood pressure for kidney disease-lower is not better. Nat Rev Nephrol. 2013 Nov; 9(11):634-5. View in: PubMed

  331. Schlaich MP, Schmieder RE, Bakris G, Blankestijn PJ, Böhm M, Campese VM, Francis DP, Grassi G, Hering D, Katholi R, Kjeldsen S, Krum H, Mahfoud F, Mancia G, Messerli FH, Narkiewicz K, Parati G, Rocha-Singh KJ, Ruilope LM, Rump LC, Sica DA, Sobotka PA, Tsioufis C, Vonend O, Weber MA, Williams B, Zeller T, Esler MD. International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol. 2013 Dec 03; 62(22):2031-45. View in: PubMed

  332. Nicholls SJ, Bakris GL, Kastelein JJ, Menon V, Williams B, Armbrecht J, Brunel P, Nicolaides M, Hsu A, Hu B, Fang H, Puri R, Uno K, Kataoka Y, Bash D, Nissen SE. Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. JAMA. 2013 Sep 18; 310(11):1135-44. View in: PubMed

  333. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013 Oct 03; 369(14):1327-35. View in: PubMed

  334. Yano Y, Bakris GL, Matsushita K, Hoshide S, Shimada K, Kario K. Both chronic kidney disease and nocturnal blood pressure associate with strokes in the elderly. Am J Nephrol. 2013; 38(3):195-203. View in: PubMed

  335. Moranne O, Bakris G, Fafin C, Favre G, Pradier C, Esnault VL. Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy. Clin J Am Soc Nephrol. 2013 Oct; 8(10):1694-701. View in: PubMed

  336. Briasoulis A, Bakris G. The future of interventional management of hypertension: threats and opportunities. Curr Vasc Pharmacol. 2014 Jan; 12(1):69-76. View in: PubMed

  337. Bhatta SS, Wroblewski KE, Agarwal KL, Sit L, Cohen EE, Seiwert TY, Karrison T, Bakris GL, Ratain MJ, Vokes EE, Maitland ML. Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. Oncologist. 2013; 18(8):965-70. View in: PubMed

  338. Rajagopalan S, Bakris GL, Abraham WT, Pitt B, Brook RD. Complete renin-angiotensin-aldosterone system (RAAS) blockade in high-risk patients: recent insights from renin blockade studies. Hypertension. 2013 Sep; 62(3):444-9. View in: PubMed

  339. Briasoulis A, Bakris G. Initial single-pill combination therapy for cardiovascular risk factor management: it is not just convenience. J Hypertens. 2013 Aug; 31(8):1537-8. View in: PubMed

  340. Briasoulis A, Oliva R, Kalaitzidis R, Flynn C, Lazich I, Schlaffer C, Bakris G. Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study. J Clin Hypertens (Greenwich). 2013 Jul; 15(7):473-9. View in: PubMed

  341. Bakris GL. The author replies. Kidney Int. 2013 Jul; 84(1):215. View in: PubMed

  342. Weber MA, Bakris GL, Weir MR, Jamerson K. Obesity, blood pressure, and cardiovascular outcomes - Authors' reply. Lancet. 2013 Jun 08; 381(9882):1982-3. View in: PubMed

  343. Bakris GL. Interventional cardiology: Indications for renal denervation: a balanced approach? Nat Rev Cardiol. 2013 Aug; 10(8):434-6. View in: PubMed

  344. Briasoulis A, Bakris G. Efficacy of baroreflex activation therapy for the treatment of resistant hypertension. EuroIntervention. 2013 May; 9 Suppl R:R136-9. View in: PubMed

  345. Elliott WJ, Egan B, Giles TD, Bakris GL, White WB, Sansone TM. Rationale for establishing a mechanism to increase reimbursement to hypertension specialists. J Clin Hypertens (Greenwich). 2013 Jun; 15(6):397-403. View in: PubMed

  346. Taler SJ, Agarwal R, Bakris GL, Flynn JT, Nilsson PM, Rahman M, Sanders PW, Textor SC, Weir MR, Townsend RR. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis. 2013 Aug; 62(2):201-13. View in: PubMed

  347. Bakris GL. Lowering blood pressure limits in patients with type 2 diabetes: is it still warranted? J Diabetes Complications. 2013 Sep-Oct; 27(5):415-6. View in: PubMed

  348. Flynn C, Bakris GL. Role of ambulatory blood pressure monitoring in hypertension and diabetes. Curr Hypertens Rep. 2013 Jun; 15(3):137-42. View in: PubMed

  349. Bakris G, Briasoulis A, Dahlof B, Jamerson K, Weber MA, Kelly RY, Hester A, Hua T, Zappe D, Pitt B. Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. Am J Cardiol. 2013 Jul 15; 112(2):255-9. View in: PubMed

  350. Weber MA, Bakris GL, Hester A, Weir MR, Hua TA, Zappe D, Dahlof B, Velazquez EJ, Pitt B, Jamerson K. Systolic blood pressure and cardiovascular outcomes during treatment of hypertension. Am J Med. 2013 Jun; 126(6):501-8. View in: PubMed

  351. Yano Y, Bakris GL. Recognition and management of masked hypertension: a review and novel approach. J Am Soc Hypertens. 2013 May-Jun; 7(3):244-52. View in: PubMed

  352. Bönner G, Bakris GL, Sica D, Weber MA, White WB, Perez A, Cao C, Handley A, Kupfer S. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens. 2013 Aug; 27(8):479-86. View in: PubMed

  353. McMullan CJ, Bakris GL, Phillips RA, Forman JP. Association of BP variability with mortality among African Americans with CKD. Clin J Am Soc Nephrol. 2013 May; 8(5):731-8. View in: PubMed

  354. de Zeeuw D, Akizawa T, Agarwal R, Audhya P, Bakris GL, Chin M, Krauth M, Lambers Heerspink HJ, Meyer CJ, McMurray JJ, Parving HH, Pergola PE, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Warnock DG, Wittes J, Chertow GM. Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON). Am J Nephrol. 2013; 37(3):212-22. View in: PubMed

  355. Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, Figueroa K, Wajs E, Usiskin K, Meininger G. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013 May; 15(5):463-73. View in: PubMed

  356. Bakris G. Clinical guidelines: blood pressure goals in T2DM: a Latin American perspective. Nat Rev Endocrinol. 2013 Mar; 9(3):138-9. View in: PubMed

  357. Flynn C, Bakris GL. Noninsulin glucose-lowering agents for the treatment of patients on dialysis. Nat Rev Nephrol. 2013 Mar; 9(3):147-53. View in: PubMed

  358. Bakris GL, Oparil S, Purkayastha D, Yadao AM, Alessi T, Sowers JR. Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2013 Feb; 15(2):92-100. View in: PubMed

  359. Briasoulis A, Bakris GL. Chronic kidney disease as a coronary artery disease risk equivalent. Curr Cardiol Rep. 2013 Mar; 15(3):340. View in: PubMed

  360. Briasoulis A, Bakris GL. The OSCAR for cardiovascular disease prevention in chronic kidney disease goes to blood pressure control. Kidney Int. 2013 Jan; 83(1):20-2. View in: PubMed

  361. Babayev R, Whaley-Connell A, Kshirsagar A, Klemmer P, Navaneethan S, Chen SC, Li S, McCullough PA, Bakris G, Bomback A. Association of race and body mass index with ESRD and mortality in CKD stages 3-4: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2013 Mar; 61(3):404-12. View in: PubMed

  362. Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, Dahlof B, Velazquez EJ, Pitt B. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet. 2013 Feb 16; 381(9866):537-45. View in: PubMed

  363. Rahman M, Greene T, Phillips RA, Agodoa LY, Bakris GL, Charleston J, Contreras G, Gabbai F, Hiremath L, Jamerson K, Kendrick C, Kusek JW, Lash JP, Lea J, Miller ER, Rostand S, Toto R, Wang X, Wright JT, Appel LJ. A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease. Hypertension. 2013 Jan; 61(1):82-8. View in: PubMed

  364. Sarafidis PA, Georgianos P, Bakris GL. Resistant hypertension--its identification and epidemiology. Nat Rev Nephrol. 2013 Jan; 9(1):51-8. View in: PubMed

  365. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC, Crowley K, Goto S, Ohman EM, Bakris GL, Perlstein TS, Kinlay S, Bhatt DL. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J. 2013 Apr; 34(16):1204-14. View in: PubMed

  366. Mentz RJ, Bakris GL, Waeber B, McMurray JJ, Gheorghiade M, Ruilope LM, Maggioni AP, Swedberg K, Piña IL, Fiuzat M, O'Connor CM, Zannad F, Pitt B. The past, present and future of renin-angiotensin aldosterone system inhibition. Int J Cardiol. 2013 Sep 01; 167(5):1677-87. View in: PubMed

  367. Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K, Struthers AD, Voors AA, Ruilope LM, Bakris GL, O'Connor CM, Gheorghiade M, Mentz RJ, Cohen-Solal A, Maggioni AP, Beygui F, Filippatos GS, Massy ZA, Pathak A, Piña IL, Sabbah HN, Sica DA, Tavazzi L, Pitt B. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J. 2012 Nov; 33(22):2782-95. View in: PubMed

  368. Bakris GL, Sica D, White WB, Cushman WC, Weber MA, Handley A, Song E, Kupfer S. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med. 2012 Dec; 125(12):1229.e1-1229.e10. View in: PubMed

  369. Oliva RV, Bakris GL. Management of hypertension in the elderly population. J Gerontol A Biol Sci Med Sci. 2012 Dec; 67(12):1343-51. View in: PubMed

  370. Cunnane RT, Bakris GL. Hypertensive goals in patients with coronary artery disease. Curr Cardiol Rep. 2012 Dec; 14(6):667-72. View in: PubMed

  371. Sarafidis PA, Bakris GL. Use of a single target blood pressure level in type 2 diabetes mellitus for all cardiovascular risk reduction: comment on "intensive and standard blood pressure targets in patients with type 2 diabetes mellitus". Arch Intern Med. 2012 Sep 24; 172(17):1304-5. View in: PubMed

  372. Briasoulis A, Bakris GL. Timing and efficacy of alternative methods of sympathetic blockade. Curr Hypertens Rep. 2012 Oct; 14(5):455-61. View in: PubMed

  373. Guralnick A, Bakris GL. Approaches for targeting blood pressure control in sleep disorders. Curr Opin Nephrol Hypertens. 2012 Sep; 21(5):469-74. View in: PubMed

  374. Bhatt DL, Bakris GL. The promise of renal denervation. Cleve Clin J Med. 2012 Jul; 79(7):498-500. View in: PubMed

  375. Polonsky TS, Bakris GL. Chronic kidney disease: a coronary heart disease equivalent? Lancet. 2012 Sep 01; 380(9844):783-5. View in: PubMed

  376. Cushman WC, Bakris GL, White WB, Weber MA, Sica D, Roberts A, Lloyd E, Kupfer S. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension. 2012 Aug; 60(2):310-8. View in: PubMed

  377. Bakris GL. Lipid disorders in uremia and dialysis. Contrib Nephrol. 2012; 178:100-105. View in: PubMed

  378. Whaley-Connell A, Shlipak MG, Inker LA, Kurella Tamura M, Bomback AS, Saab G, Szpunar SM, McFarlane SI, Li S, Chen SC, Norris K, Bakris GL, McCullough PA. Awareness of kidney disease and relationship to end-stage renal disease and mortality. Am J Med. 2012 Jul; 125(7):661-9. View in: PubMed

  379. Kandzari DE, Bhatt DL, Sobotka PA, O'Neill WW, Esler M, Flack JM, Katzen BT, Leon MB, Massaro JM, Negoita M, Oparil S, Rocha-Singh K, Straley C, Townsend RR, Bakris G. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol. 2012 Sep; 35(9):528-35. View in: PubMed

  380. Sica D, Bakris GL, White WB, Weber MA, Cushman WC, Huang P, Roberts A, Kupfer S. Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich). 2012 May; 14(5):284-92. View in: PubMed

  381. Doumas M, Anyfanti P, Bakris G. Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective. J Hypertens. 2012 May; 30(5):874-6. View in: PubMed

  382. Gulati M, Black HR, Arnsdorf MF, Shaw LJ, Bakris GL. Kidney dysfunction, cardiorespiratory fitness, and the risk of death in women. J Womens Health (Larchmt). 2012 Sep; 21(9):917-24. View in: PubMed

  383. Sharma AM, Bakris G, Neutel JM, Littlejohn TW, Kobe M, Ting N, Ley L. Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial. Clin Ther. 2012 Mar; 34(3):537-51. View in: PubMed

  384. Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012 Mar-Apr; 6(2):152-8. View in: PubMed

  385. Ahmed A, Fonarow GC, Zhang Y, Sanders PW, Allman RM, Arnett DK, Feller MA, Love TE, Aban IB, Levesque R, Ekundayo OJ, Dell'Italia LJ, Bakris GL, Rich MW. Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease. Am J Med. 2012 Apr; 125(4):399-410. View in: PubMed

  386. Oliva RV, Bakris GL. Can ambulatory blood pressure serve as a biomarker for presence of chronic kidney disease? J Hypertens. 2012 Mar; 30(3):466-7. View in: PubMed

  387. Steingart RM, Bakris GL, Chen HX, Chen MH, Force T, Ivy SP, Leier CV, Liu G, Lenihan D, Lindenfeld J, Maitland ML, Remick SC, Tang WH. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J. 2012 Feb; 163(2):156-63. View in: PubMed

  388. Whaley-Connell A, Bomback AS, McFarlane SI, Li S, Roberts T, Chen SC, Collins AJ, Norris K, Bakris GL, Sowers JR, McCullough PA. Diabetic Cardiovascular Disease Predicts Chronic Kidney Disease Awareness in the Kidney Early Evaluation Program. Cardiorenal Med. 2011; 1(1):45-52. View in: PubMed

  389. Saab G, Whaley-Connell A, Bombeck A, Kurella Tamura M, Li S, Chen SC, McFarlane SI, Sowers JR, Norris K, Bakris GL, McCullough PA. The Association between Parathyroid Hormone Levels and the Cardiorenal Metabolic Syndrome in Non-Diabetic Chronic Kidney Disease. Cardiorenal Med. 2011; 1(2):123-130. View in: PubMed

  390. Flynn C, Bakris GL. Interaction between Adiponectin and Aldosterone. Cardiorenal Med. 2011; 1(2):96-101. View in: PubMed

  391. Kalaitzidis RG, Bakris GL. Pros and cons of aggressive blood pressure lowering in patients with type 2 diabetes. Curr Vasc Pharmacol. 2012 Mar; 10(2):156-61. View in: PubMed

  392. Masi C, Hamlish T, Davis A, Bordenave K, Brown S, Perea B, Aduana G, Wolfe M, Bakris G, Johnson D. Using an established telehealth model to train urban primary care providers on hypertension management. J Clin Hypertens (Greenwich). 2012 Jan; 14(1):45-50. View in: PubMed

  393. Peralta CA, Norris KC, Li S, Chang TI, Tamura MK, Jolly SE, Bakris G, McCullough PA, Shlipak M. Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2012 Jan 09; 172(1):41-7. View in: PubMed

  394. Weir MR, Bakris GL, Weber MA, Dahlof B, Devereux RB, Kjeldsen SE, Pitt B, Wright JT, Kelly RY, Hua TA, Hester RA, Velazquez E, Jamerson KA. Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney Int. 2012 Mar; 81(6):568-76. View in: PubMed

  395. Bakris GL. Hypertension in 2011: New insights--from risk factors to treatment implications. Nat Rev Cardiol. 2011 Dec 13; 9(2):75-7. View in: PubMed

  396. Sarafidis PA, Bakris G. A reappraisal of renin-angiotensin system blockade on microalbuminuria development: do they offer anything unique? J Hypertens. 2012 Jan; 30(1):48-50. View in: PubMed

  397. Mensah GA, Bakris G. The United Nations high level meeting addresses noncommunicable diseases, but where is hypertension? J Clin Hypertens (Greenwich). 2011 Nov; 13(11):787-90. View in: PubMed

  398. White WB, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Fleck P, Heller S, Mehta C, Nissen SE, Perez A, Wilson C, Zannad F. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J. 2011 Oct; 162(4):620-626.e1. View in: PubMed

  399. Lazich I, Sarafidis P, de Guzman E, Patel A, Oliva R, Bakris G. Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study. Diabetes Obes Metab. 2012 Feb; 14(2):181-6. View in: PubMed

  400. Guichard JL, Desai RV, Ahmed MI, Mujib M, Fonarow GC, Feller MA, Ekundayo OJ, Bittner V, Aban IB, White M, Aronow WS, Love TE, Bakris GL, Zieman SJ, Ahmed A. Isolated diastolic hypotension and incident heart failure in older adults. Hypertension. 2011 Nov; 58(5):895-901. View in: PubMed

  401. Bhavsar NA, Appel LJ, Kusek JW, Contreras G, Bakris G, Coresh J, Astor BC. Comparison of measured GFR, serum creatinine, cystatin C, and beta-trace protein to predict ESRD in African Americans with hypertensive CKD. Am J Kidney Dis. 2011 Dec; 58(6):886-93. View in: PubMed

  402. Flynn C, Bakris GL. Blood pressure targets for patients with diabetes or kidney disease. Curr Hypertens Rep. 2011 Dec; 13(6):452-5. View in: PubMed

  403. Lazich I, Bakris GL. Endothelin antagonism in patients with resistant hypertension and hypertension nephropathy. Contrib Nephrol. 2011; 172:223-234. View in: PubMed

  404. Kjeldsen SE, Jamerson KA, Bakris GL, Pitt B, Dahlöf B, Velazquez EJ, Hua TA, Kelly RY, Zappe D, Hester A, Tuomilehto J, Ostergren J, Ibsen H, Weber M. Predictors of systolic BP PubMed

  405. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, de Leeuw PW, Sica DA. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011 Aug 09; 58(7):765-73. View in: PubMed

  406. Brown WV, Bakris G, Lerma E, Chertow G. Assessment and management of vascular disease risk in patients with chronic kidney disease. J Clin Lipidol. 2011 Jul-Aug; 5(4):251-60. View in: PubMed

  407. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Ann Forciea M, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ, Harrington RA, Bates ER, Bhatt DL, Bridges CR, Eisenberg MJ, Ferrari VA, Fisher JD, Gardner TJ, Gentile F, Gilson MF, Hlatky MA, Jacobs AK, Kaul S, Moliterno DJ, Mukherjee D, Rosenson RS, Stein JH, Weitz HH, Wesley DJ. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Soc Hypertens. 2011 Jul-Aug; 5(4):259-352. View in: PubMed

  408. Bakris GL. American Society of Hypertension, Inc: Leadership message. J Clin Hypertens (Greenwich). 2011 Jul; 13(7):533. View in: PubMed

  409. Sica D, White WB, Weber MA, Bakris GL, Perez A, Cao C, Handley A, Kupfer S. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2011 Jul; 13(7):467-72. View in: PubMed

  410. Lazich I, Bakris GL. Newer renin-angiotensin-aldosterone system blocker combinations: is there an advantage? Curr Opin Nephrol Hypertens. 2011 Sep; 20(5):471-5. View in: PubMed

  411. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, Lernmark A, Metzger BE, Nathan DM. Executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2011 Jun; 57(6):793-8. View in: PubMed

  412. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, Lernmark A, Metzger BE, Nathan DM. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2011 Jun; 57(6):e1-e47. View in: PubMed

  413. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, Lernmark A, Metzger BE, Nathan DM. Position statement executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care. 2011 Jun; 34(6):1419-23. View in: PubMed

  414. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, Lernmark A, Metzger BE, Nathan DM. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care. 2011 Jun; 34(6):e61-99. View in: PubMed

  415. Bakris GL. Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin Proc. 2011 May; 86(5):444-56. View in: PubMed

  416. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Ann Forciea M, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol. 2011 May 17; 57(20):2037-114. View in: PubMed

  417. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Forciea MA, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ, Harrington RA. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2011 May 31; 123(21):2434-506. View in: PubMed

  418. Bakris GL. Blood pressure targets in diabetes: is this the time for change?--CON (Rebuttal). J Clin Hypertens (Greenwich). 2011 Apr; 13(4):268-9. View in: PubMed

  419. Bakris GL. CON: blood pressure treatment goal for patients with diabetes should be PubMed

  420. Ruilope LM, Bakris GL. Renal function and target organ damage in hypertension. Eur Heart J. 2011 Jul; 32(13):1599-604. View in: PubMed

  421. Schmieder RE, Bakris G, Weir MR. Telmisartan in incipient and overt diabetic renal disease. J Nephrol. 2011 May-Jun; 24(3):263-73. View in: PubMed

  422. White WB, Schnitzer TJ, Bakris GL, Frayssinet H, Duquesroix B, Weber M. Effects of naproxcinod on blood pressure in patients with osteoarthritis. Am J Cardiol. 2011 May 01; 107(9):1338-45. View in: PubMed

  423. Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J Clin Hypertens (Greenwich). 2011 Mar; 13(3):146-54. View in: PubMed

  424. Stevens LA, Li S, Kurella Tamura M, Chen SC, Vassalotti JA, Norris KC, Whaley-Connell AT, Bakris GL, McCullough PA. Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011 Mar; 57(3 Suppl 2):S9-16. View in: PubMed

  425. McCullough PA, Brown WW, Gannon MR, Vassalotti JA, Collins AJ, Chen SC, Bakris GL, Whaley-Connell AT. Sustainable community-based CKD screening methods employed by the National Kidney Foundation's Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011 Mar; 57(3 Suppl 2):S4-8. View in: PubMed

  426. McFarlane SI, McCullough PA, Sowers JR, Soe K, Chen SC, Li S, Vassalotti JA, Stevens LA, Salifu MO, Kurella Tamura M, Bomback AS, Norris KC, Collins AJ, Bakris GL, Whaley-Connell AT. Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: prevalence of and risk factors for diabetes mellitus in CKD in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011 Mar; 57(3 Suppl 2):S24-31. View in: PubMed

  427. McCullough PA, Vassalotti JA, Collins AJ, Chen SC, Bakris GL, Whaley-Connell AT. National Kidney Foundation's Kidney Early Evaluation Program (KEEP) annual data report 2010: executive summary. Am J Kidney Dis. 2011 Mar; 57(3 Suppl 2):S1-3. View in: PubMed

  428. Udani SM, Bakris GL. Do fibrates truly preserve kidney function? Nat Rev Endocrinol. 2011 Mar; 7(3):130-1. View in: PubMed

  429. White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, Kupfer S. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011 Mar; 57(3):413-20. View in: PubMed

  430. Bakris GL, Sica D, Weber M, White WB, Roberts A, Perez A, Cao C, Kupfer S. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich). 2011 Feb; 13(2):81-8. View in: PubMed

  431. Lazich I, Bakris G. Initial combination antihypertensives: let's ACCELERATE. Lancet. 2011 Jan 22; 377(9762):278-9. View in: PubMed

  432. McCullough PA, Whaley-Connell A, Brown WW, Collins AJ, Chen SC, Li S, Norris KC, Jurkovitz C, McFarlane S, Obialo C, Sowers J, Stevens L, Vassalotti JA, Bakris GL. Cardiovascular risk modification in participants with coronary disease screened by the Kidney Early Evaluation Program. Intern Med J. 2010 Dec; 40(12):833-41. View in: PubMed

  433. Jamerson KA, Devereux R, Bakris GL, Dahlöf B, Pitt B, Velazquez EJ, Weir M, Kelly RY, Hua TA, Hester A, Weber MA. Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. Hypertension. 2011 Feb; 57(2):174-9. View in: PubMed

  434. Udani S, Lazich I, Bakris GL. Epidemiology of hypertensive kidney disease. Nat Rev Nephrol. 2011 Jan; 7(1):11-21. View in: PubMed

  435. Miller AB, Reichek N, St John Sutton M, Iyengar M, Henderson LS, Tarka EA, Bakris GL. Importance of blood pressure control in left ventricular mass regression. J Am Soc Hypertens. 2010 Nov-Dec; 4(6):302-10. View in: PubMed

  436. Vasisht KP, Chen SC, Peng Y, Bakris GL. Limitations of metformin use in patients with kidney disease: are they warranted? Diabetes Obes Metab. 2010 Dec; 12(12):1079-83. View in: PubMed

  437. Mensah GA, Bakris G. Treatment and control of high blood pressure in adults. Cardiol Clin. 2010 Nov; 28(4):609-22. View in: PubMed

  438. Singh M, Mensah GA, Bakris G. Pathogenesis and clinical physiology of hypertension. Cardiol Clin. 2010 Nov; 28(4):545-59. View in: PubMed

  439. Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm RH, Hall WD, Jones WE, Kountz DS, Lea JP, Nasser S, Nesbitt SD, Saunders E, Scisney-Matlock M, Jamerson KA. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension. 2010 Nov; 56(5):780-800. View in: PubMed

  440. Bakris GL, Lindholm LH, Black HR, Krum H, Linas S, Linseman JV, Arterburn S, Sager P, Weber M. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension. 2010 Nov; 56(5):824-30. View in: PubMed

  441. Burney B, Oliva R, Zorn KC, Bakris G. Hypertension following kidney injury. J Clin Hypertens (Greenwich). 2010 Sep; 12(9):727-30. View in: PubMed

  442. Bakris GL, Iyengar M, Lukas MA, Ordronneau P, Weber MA. Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study. J Clin Hypertens (Greenwich). 2010 Sep; 12(9):678-86. View in: PubMed

  443. Contreras G, Hu B, Astor BC, Greene T, Erlinger T, Kusek JW, Lipkowitz M, Lewis JA, Randall OS, Hebert L, Wright JT, Kendrick CA, Gassman J, Bakris G, Kopple JD, Appel LJ. Malnutrition-inflammation modifies the relationship of cholesterol with cardiovascular disease. J Am Soc Nephrol. 2010 Dec; 21(12):2131-42. View in: PubMed

  444. Appel LJ, Wright JT, Greene T, Agodoa LY, Astor BC, Bakris GL, Cleveland WH, Charleston J, Contreras G, Faulkner ML, Gabbai FB, Gassman JJ, Hebert LA, Jamerson KA, Kopple JD, Kusek JW, Lash JP, Lea JP, Lewis JB, Lipkowitz MS, Massry SG, Miller ER, Norris K, Phillips RA, Pogue VA, Randall OS, Rostand SG, Smogorzewski MJ, Toto RD, Wang X. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010 Sep 02; 363(10):918-29. View in: PubMed

  445. Bomback AS, Rekhtman Y, Whaley-Connell AT, Kshirsagar AV, Sowers JR, Chen SC, Li S, Chinnaiyan KM, Bakris GL, McCullough PA. Gestational diabetes mellitus alone in the absence of subsequent diabetes is associated with microalbuminuria: results from the Kidney Early Evaluation Program (KEEP). Diabetes Care. 2010 Dec; 33(12):2586-91. View in: PubMed

  446. Weir MR, Bakris GL. Optimal blood pressure for a patient with type 2 diabetes mellitus: insight from the ACCORD study. Curr Hypertens Rep. 2010 Oct; 12(5):313-5. View in: PubMed

  447. Bakris G, Vassalotti J, Ritz E, Wanner C, Stergiou G, Molitch M, Nesto R, Kaysen GA, Sowers JR. National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney Int. 2010 Oct; 78(8):726-36. View in: PubMed

  448. Hart PD, Bakris GL. Hypertensive nephropathy: prevention and treatment recommendations. Expert Opin Pharmacother. 2010 Nov; 11(16):2675-86. View in: PubMed

  449. Bakris GL. Leadership message. Forging ahead into the new healthcare frontier. J Clin Hypertens (Greenwich). 2010 Aug; 12(8):631-2. View in: PubMed

  450. DeVore AD, Sorrentino M, Arnsdorf MF, Ward RP, Bakris GL, Blankstein R. Predictors of hypertension control in a diverse general cardiology practice. J Clin Hypertens (Greenwich). 2010 Aug; 12(8):570-7. View in: PubMed

  451. Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE, Eagle KA, Hermann LK, Isselbacher EM, Kazerooni EA, Kouchoukos NT, Lytle BW, Milewicz DM, Reich DL, Sen S, Shinn JA, Svensson LG, Williams DM. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Catheter Cardiovasc Interv. 2010 Aug 01; 76(2):E43-86. View in: PubMed

  452. Chugh A, Bakris G. Intensive lowering of systolic blood pressure to a target of less than 120 mm Hg has no effect on the rate of fatal and non-fatal major cardiovascular events in high-risk patients with type 2 diabetes. Evid Based Med. 2010 Oct; 15(5):142-3. View in: PubMed

  453. Bakris GL. Dual RAAS blockade is desirable in kidney disease: con. Kidney Int. 2010 Sep; 78(6):546-9. View in: PubMed

  454. Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE, Eagle KA, Hermann LK, Isselbacher EM, Kazerooni EA, Kouchoukos NT, Lytle BW, Milewicz DM, Reich DL, Sen S, Shinn JA, Svensson LG, Williams DM. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Anesth Analg. 2010 Aug; 111(2):279-315. View in: PubMed

  455. Hopkins KA, Bakris GL. Lower blood pressure goals in high-risk cardiovascular patients: are they defensible? Cardiol Clin. 2010 Aug; 28(3):447-52. View in: PubMed

  456. Bakris GL. Diabetes, the kidney, and cardiovascular risk. Preface. Cardiol Clin. 2010 Aug; 28(3):xi. View in: PubMed

  457. Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, Velazquez EJ, Dahlöf B, Kelly RY, Hua TA, Hester A, Pitt B. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol. 2010 Jun 29; 56(1):77-85. View in: PubMed

  458. Taylor AA, Bakris GL. The role of vasodilating beta-blockers in patients with hypertension and the cardiometabolic syndrome. Am J Med. 2010 Jul; 123(7 Suppl 1):S21-6. View in: PubMed

  459. Bakris GL, Basile JN, Giles TD, Taylor AA. The role of nitric oxide in improving endothelial function and cardiovascular health: focus on nebivolol. Am J Med. 2010 Jul; 123(7 Suppl 1):S2-8. View in: PubMed

  460. Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, Pepine CJ. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010 Jul 07; 304(1):61-8. View in: PubMed

  461. Jamerson KA, Bakris GL, Weber MA. 24-hour ambulatory blood pressure in the ACCOMPLISH trial. N Engl J Med. 2010 Jul 01; 363(1):98. View in: PubMed

  462. Ruilope L, Izzo J, Haller H, Waeber B, Oparil S, Weber M, Bakris G, Sowers J. Prevention of microalbuminuria in patients with type 2 diabetes: what do we know? J Clin Hypertens (Greenwich). 2010 Jun; 12(6):422-30. View in: PubMed

  463. Bakris GL, Bidani A. More complete renin-angiotensin system blockade: better outcomes or smoke and mirrors. J Hypertens. 2010 Jul; 28(7):1382-3. View in: PubMed

  464. Hopkins KA, Bakris GL. Fixed-dose combination and chronic kidney disease progression: which is the best? Curr Opin Nephrol Hypertens. 2010 Sep; 19(5):450-5. View in: PubMed

  465. Kalaitzidis RG, Bakris GL. Serum creatinine vs. albuminuria as biomarkers for the estimation of cardiovascular risk. Curr Vasc Pharmacol. 2010 Sep; 8(5):604-11. View in: PubMed

  466. Weir MR, Bakris GL. Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol. 2010; 31(5):469-70. View in: PubMed

  467. Bakris GL. Is blockade of the renin-angiotensin system appropriate for all patients with diabetes? J Am Soc Hypertens. 2009 Sep-Oct; 3(5):288-90. View in: PubMed

  468. Bakris GL, Sowers JR. Treatment of hypertension in patients with diabetes-an update. J Am Soc Hypertens. 2009 Mar-Apr; 3(2):150-5. View in: PubMed

  469. Bakris GL, Ritz E. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. J Am Soc Hypertens. 2009 Mar-Apr; 3(2):80-3. View in: PubMed

  470. Gradman AH, Basile JN, Carter BL, Bakris GL, Materson BJ, Black HR, Izzo JL, Oparil S, Weber MA. Combination therapy in hypertension. J Am Soc Hypertens. 2010 Mar-Apr; 4(2):90-8. View in: PubMed

  471. Bakris GL, Sowers JR, Glies TD, Black HR, Izzo JL, Materson BJ, Oparil S, Weber MA. Treatment of hypertension in patients with diabetes--an update. J Am Soc Hypertens. 2010 Mar-Apr; 4(2):62-7. View in: PubMed

  472. Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J Am Soc Hypertens. 2010 Jan-Feb; 4(1):42-50. View in: PubMed

  473. Iyer AS, Ahmed MI, Filippatos GS, Ekundayo OJ, Aban IB, Love TE, Nanda NC, Bakris GL, Fonarow GC, Aronow WS, Ahmed A. Uncontrolled hypertension and increased risk for incident heart failure in older adults with hypertension: findings from a propensity-matched prospective population study. J Am Soc Hypertens. 2010 Jan-Feb; 4(1):22-31. View in: PubMed

  474. Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE, Eagle KA, Hermann LK, Isselbacher EM, Kazerooni EA, Kouchoukos NT, Lytle BW, Milewicz DM, Reich DL, Sen S, Shinn JA, Svensson LG, Williams DM. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology,American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons,and Society for Vascular Medicine. J Am Coll Cardiol. 2010 Apr 06; 55(14):e27-e129. View in: PubMed

  475. Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, Ivy SP, Leier CV, Lindenfeld J, Liu G, Remick SC, Steingart R, Tang WH. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010 May 05; 102(9):596-604. View in: PubMed

  476. Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE, Eagle KA, Hermann LK, Isselbacher EM, Kazerooni EA, Kouchoukos NT, Lytle BW, Milewicz DM, Reich DL, Sen S, Shinn JA, Svensson LG, Williams DM. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation. 2010 Apr 06; 121(13):e266-369. View in: PubMed

  477. Mak RH, Bakris G. Pediatrics: Masked hypertension: a risk factor in children with CKD. Nat Rev Nephrol. 2010 Mar; 6(3):132-4. View in: PubMed

  478. Bakris GL. Overview of the KEEP international articles. Kidney Int Suppl. 2010 Mar; (116):S1. View in: PubMed

  479. Bomback AS, Kshirsagar AV, Whaley-Connell AT, Chen SC, Li S, Klemmer PJ, McCullough PA, Bakris GL. Racial differences in kidney function among individuals with obesity and metabolic syndrome: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2010 Mar; 55(3 Suppl 2):S4-S14. View in: PubMed

  480. Stevens LA, Li S, Wang C, Huang C, Becker BN, Bomback AS, Brown WW, Burrows NR, Jurkovitz CT, McFarlane SI, Norris KC, Shlipak M, Whaley-Connell AT, Chen SC, Bakris GL, McCullough PA. Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2010 Mar; 55(3 Suppl 2):S23-33. View in: PubMed

  481. McCullough PA, Vassalotti JA, Collins AJ, Chen SC, Bakris GL. National Kidney Foundation's Kidney Early Evaluation Program (KEEP) annual data report 2009: executive summary. Am J Kidney Dis. 2010 Mar; 55(3 Suppl 2):S1-3. View in: PubMed

  482. Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010 Apr 03; 375(9721):1173-81. View in: PubMed

  483. Vassalotti JA, Li S, McCullough PA, Bakris GL. Kidney early evaluation program: a community-based screening approach to address disparities in chronic kidney disease. Semin Nephrol. 2010 Jan; 30(1):66-73. View in: PubMed

  484. Mak RH, Flynn J, Bakris G. Pediatrics: blood pressure target for renoprotection in children. Nat Rev Nephrol. 2010 Feb; 6(2):67-8. View in: PubMed

  485. Bowling CB, Pitt B, Ahmed MI, Aban IB, Sanders PW, Mujib M, Campbell RC, Love TE, Aronow WS, Allman RM, Bakris GL, Ahmed A. Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail. 2010 Mar; 3(2):253-60. View in: PubMed

  486. Bakris G. Are there effects of renin-angiotensin system antagonists beyond blood pressure control? Am J Cardiol. 2010 Jan 04; 105(1 Suppl):21A-9A. View in: PubMed

  487. Oliva R, Angelos P, Kaplan E, Bakris G. Pheochromocytoma in pregnancy: a case series and review. Hypertension. 2010 Mar; 55(3):600-6. View in: PubMed

  488. Whaley-Connell A, Pavey BS, McCullough PA, Saab G, Li S, McFarlane SI, Chen SC, Vassalotti JA, Collins AJ, Bakris G, Sowers JR. Dysglycemia predicts cardiovascular and kidney disease in the Kidney Early Evaluation Program. J Clin Hypertens (Greenwich). 2010 Jan; 12(1):51-8. View in: PubMed

  489. Burney BO, Bakris GL. Hypertension and its management in the elderly. Semin Nephrol. 2009 Nov; 29(6):604-9. View in: PubMed

  490. Hopkins K, Bakris GL. Hypertension goals in advanced-stage kidney disease. Clin J Am Soc Nephrol. 2009 Dec; 4 Suppl 1:S92-4. View in: PubMed

  491. Kalaitzidis RG, Bakris GL. Prehypertension: is it relevant for nephrologists? Kidney Int. 2010 Feb; 77(3):194-200. View in: PubMed

  492. Duka I, Bakris G. Inhibiting the renin-angiotensin system in patients with type 1 diabetes: is it worth it? Pol Arch Med Wewn. 2009 Nov; 119(11):692-3. View in: PubMed

  493. Bhatnagar V, Garcia EP, O'Connor DT, Brophy VH, Alcaraz J, Richard E, Bakris GL, Middleton JP, Norris KC, Wright J, Hiremath L, Contreras G, Appel LJ, Lipkowitz MS. CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease. Am J Nephrol. 2010; 31(2):95-103. View in: PubMed

  494. Bakris GL. Retraction statement. Am J Nephrol. 2009; 30(6):563. View in: PubMed

  495. Kalaitzidis R, Bakris G. Pathogenesis and treatment of microalbuminuria in patients with diabetes: the road ahead. J Clin Hypertens (Greenwich). 2009 Nov; 11(11):636-43. View in: PubMed

  496. Kalaitzidis RG, Bakris GL. The current state of RAAS blockade in the treatment of hypertension and proteinuria. Curr Cardiol Rep. 2009 Nov; 11(6):436-42. View in: PubMed

  497. Bakris GL, Cooper-Dehoff RM, Zhou Q, Kupfer S, Champion A, Pepine CJ. Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers. Am J Cardiovasc Drugs. 2007; 7 Suppl 1:25-9. View in: PubMed

  498. Roberts WC, Bakris GL, Black HR, Sica DA, Sulkes DJ. The editor's roundtable: prehypertension. Am J Cardiol. 2009 Oct 15; 104(8):1105-15. View in: PubMed

  499. Saab G, Whaley-Connell A, McFarlane SI, Li S, Chen SC, Sowers JR, McCullough PA, Bakris GL. Obesity is associated with increased parathyroid hormone levels independent of glomerular filtration rate in chronic kidney disease. Metabolism. 2010 Mar; 59(3):385-9. View in: PubMed

  500. Weinberg JM, Appel LJ, Bakris G, Gassman JJ, Greene T, Kendrick CA, Wang X, Lash J, Lewis JA, Pogue V, Thornley-Brown D, Phillips RA. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med. 2009 Sep 28; 169(17):1587-94. View in: PubMed

  501. Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, Linseman JV, Wiens BL, Warren MS, Lindholm LH. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Oct 24; 374(9699):1423-31. View in: PubMed

  502. Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol. 2009; 30(5):418-24. View in: PubMed

  503. Bakris G. Hypertension guidelines and chronic kidney disease: physicians, please follow directions. Curr Hypertens Rep. 2009 Oct; 11(5):301-2. View in: PubMed

  504. Bakris G. Home blood pressure monitoring to manage hypertension in patients with nephropathy: the time has arrived. Curr Hypertens Rep. 2009 Oct; 11(5):299-300. View in: PubMed

  505. Bakris GL, Kuritzky L. Monitoring and managing urinary albumin excretion: practical advice for primary care clinicians. Postgrad Med. 2009 Jul; 121(4):51-60. View in: PubMed

  506. Bakris GL. The future of blood pressure control in a population with a growing girth. Curr Opin Nephrol Hypertens. 2009 Sep; 18(5):379-80. View in: PubMed

  507. Kalaitzidis R, Bakris GL. Effects of angiotensin II receptor blockers on diabetic nephropathy. J Hypertens Suppl. 2009 Jul; 27(5):S15-21. View in: PubMed

  508. Kalaitzidis R, Bakris GL. Lower blood pressure goals for cardiovascular and renal risk reduction: are they defensible? J Clin Hypertens (Greenwich). 2009 Jul; 11(7):345-7. View in: PubMed

  509. Kalaitzidis RG, Bakris GL. Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease? Curr Opin Nephrol Hypertens. 2009 Sep; 18(5):386-91. View in: PubMed

  510. Kalaitzidis R, Bakris G. Management of hypertension in patients with diabetes: the place of angiotensin-II receptor blockers. Diabetes Obes Metab. 2009 Aug; 11(8):757-69. View in: PubMed

  511. Zanchetti A, Mancia G, Black HR, Oparil S, Waeber B, Schmieder RE, Bakris GL, Messerli FH, Kjeldsen SE, Ruilope LM. Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. J Hypertens. 2009 Apr; 27(4):673-9. View in: PubMed

  512. Ahmed MI, Ekundayo OJ, Mujib M, Campbell RC, Sanders PW, Pitt B, Perry GJ, Bakris G, Aban I, Love TE, Aronow WS, Ahmed A. Mild hyperkalemia and outcomes in chronic heart failure: a propensity matched study. Int J Cardiol. 2010 Oct 29; 144(3):383-8. View in: PubMed

  513. Dronovalli S, Burney BO, Bakris GL. Glycemic control and cardiovascular disease in chronic kidney disease. Curr Diab Rep. 2009 Jun; 9(3):243-8. View in: PubMed

  514. Bakris G. An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade. J Cardiovasc Pharmacol. 2009 May; 53(5):379-87. View in: PubMed

  515. Sarafidis PA, Bakris GL. Does evidence support renin-angiotensin system blockade for slowing nephropathy progression in elderly persons? Ann Intern Med. 2009 May 19; 150(10):731-3. View in: PubMed

  516. Burney BO, Kalaitzidis RG, Bakris GL. Novel therapies of diabetic nephropathy. Curr Opin Nephrol Hypertens. 2009 Mar; 18(2):107-11. View in: PubMed

  517. Khosla N, Kalaitzidis R, Bakris GL. The kidney, hypertension, and remaining challenges. Med Clin North Am. 2009 May; 93(3):697-715, Table of Contents. View in: PubMed

  518. Bakris GL, Ritz E. The message for World Kidney Day 2009: hypertension and kidney disease, a marriage that should be prevented. Iran J Kidney Dis. 2009 Jan; 3(1):7-10. View in: PubMed

  519. Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009 Jun; 75(12):1272-1277. View in: PubMed

  520. Bakris GL, Ritz E. The message for World Kidney Day 2009: Hypertension and kidney disease: a marriage that should be prevented. Nephrology (Carlton). 2009 Feb; 14(1):49-51. View in: PubMed

  521. Kalaitzidis R, Bakris G. Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy? Postgrad Med. 2009 Mar; 121(2):77-88. View in: PubMed

  522. Bakris GL, Ritz E. Hypertension: the message of World Kidney Day 2009. Nat Rev Nephrol. 2009 Apr; 5(4):188-90. View in: PubMed

  523. Bakris GL, Ritz E. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. J Clin Hypertens (Greenwich). 2009 Mar; 11(3):144-7. View in: PubMed

  524. Bhuriya R, Li S, Chen SC, McCullough PA, Bakris GL. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S3-10. View in: PubMed

  525. Kalaitzidis R, Li S, Wang C, Chen SC, McCullough PA, Bakris GL. Hypertension in early-stage kidney disease: an update from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S22-31. View in: PubMed

  526. Whaley-Connell A, Sowers JR, McCullough PA, Roberts T, McFarlane SI, Chen SC, Li S, Wang C, Collins AJ, Bakris GL. Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S11-21. View in: PubMed

  527. Bakris GL, McCullough PA, Collins AJ. Executive summary: Kidney Early Evaluation Program (KEEP) 2008 annual data report. Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S1-2. View in: PubMed

  528. Ritz E, Bakris G. World Kidney Day: hypertension and chronic kidney disease. Lancet. 2009 Apr 04; 373(9670):1157-8. View in: PubMed

  529. Bakris GL, Ritz E. The message for World Kidney Day 2009: hypertension and kidney disease--a marriage that should be prevented. Clin Nephrol. 2009 Mar; 71(3):239-43. View in: PubMed

  530. Bakris GL, Ritz E. Hypertension and kidney disease: a combination that should be prevented. Nephrol News Issues. 2009 Feb; 23(2):42, 44, 46. View in: PubMed

  531. Bakris GL, Ritz E. The message for World Kidney Day 2009: hypertension and kidney disease--a marriage that should be prevented. J Hypertens. 2009 Mar; 27(3):666-9. View in: PubMed

  532. Bakris GL, Ritz E. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. Am J Nephrol. 2009; 30(1):95-8. View in: PubMed

  533. Bakris GL, Ritz E. The message for World Kidney Day 2009. Hypertension and kidney disease: a marriage that should be prevented. Nephron Clin Pract. 2009; 111(2):c155-8. View in: PubMed

  534. Bakris GL, Ritz E. The message for World Kidney Day 2009: Hypertension and kidney disease: a marriage that should be prevented. Kidney Blood Press Res. 2009; 32(1):67-70. View in: PubMed

  535. Bakris GL, Ritz E. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. Blood Purif. 2009; 27(2):231-4. View in: PubMed

  536. Bakris GL, Ritz E. World Kidney Day 2009: hypertension and kidney disease is a marriage that should be prevented. Am J Kidney Dis. 2009 Mar; 53(3):373-6. View in: PubMed

  537. Bakris GL, Ritz E. The message for World Kidney Day 2009: Hypertension and kidney disease: a marriage that should be prevented. Nephrol Dial Transplant. 2009 Mar; 24(3):695-7. View in: PubMed

  538. Bakris GL, Ritz E. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. Kidney Int. 2009 Mar; 75(5):449-52. View in: PubMed

  539. Bakris GL, Ritz E. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. Clin J Am Soc Nephrol. 2009 Mar; 4(3):517-9. View in: PubMed

  540. Ekundayo OJ, Dell'Italia LJ, Sanders PW, Arnett D, Aban I, Love TE, Filippatos G, Anker SD, Lloyd-Jones DM, Bakris G, Mujib M, Ahmed A. Association between hyperuricemia and incident heart failure among older adults: a propensity-matched study. Int J Cardiol. 2010 Jul 23; 142(3):279-87. View in: PubMed

  541. Kalaitzidis RG, Sarafidis PA, Bakris GL. Effects of thiazolidinediones beyond glycaemic control. Curr Pharm Des. 2009; 15(5):529-36. View in: PubMed

  542. Bakris GL, Ritz E. The message for World Kidney Day 2009: hypertension and kidney disease-a marriage that should be prevented. Clin Exp Nephrol. 2009 Feb; 13(1):96-9. View in: PubMed

  543. Bakris GL, Ritz E. The message for World Kidney Day 2009: hypertension and kidney disease--a marriage that should be prevented. J Hum Hypertens. 2009 Mar; 23(3):222-5. View in: PubMed

  544. Hopkins K, Bakris GL. Assessing blood pressure control in dialysis patients: finally a step forward. Hypertension. 2009 Mar; 53(3):448-9. View in: PubMed

  545. Bakris GL, Ritz E. The message for World Kidney Day 2009: hypertension and kidney disease-a marriage that should be prevented. Pediatr Nephrol. 2009 Mar; 24(3):427-30. View in: PubMed

  546. Ekundayo OJ, Adamopoulos C, Ahmed MI, Pitt B, Young JB, Fleg JL, Love TE, Sui X, Perry GJ, Siscovick DS, Bakris G, Ahmed A. Oral potassium supplement use and outcomes in chronic heart failure: a propensity-matched study. Int J Cardiol. 2010 May 28; 141(2):167-74. View in: PubMed

  547. Bhatnagar V, O'Connor DT, Brophy VH, Schork NJ, Richard E, Salem RM, Nievergelt CM, Bakris GL, Middleton JP, Norris KC, Wright J, Hiremath L, Contreras G, Appel LJ, Lipkowitz MS. G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: sex-specificity and interactions. Am J Hypertens. 2009 Mar; 22(3):332-8. View in: PubMed

  548. Bakris GL, Ritz E. The message for World Kidney Day 2009: Hypertension and kidney disease: a marriage that should be prevented. Arch Iran Med. 2009 Jan; 12(1):102-5. View in: PubMed

  549. Bakris GL. ASH: renaissance of a society -- a movement of vigorous renewal. J Clin Hypertens (Greenwich). 2008 Oct; 10(10):808. View in: PubMed

  550. Kalaitzidis R, Bakris G. Should nephrologists use beta-blockers? A perspective. Nephrol Dial Transplant. 2009 Mar; 24(3):701-2. View in: PubMed

  551. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008 Dec 04; 359(23):2417-28. View in: PubMed

  552. Bakris G, Hester A, Weber M, Dahlof B, Pitt B, Velasquez E, Staikos-Byrne L, Shi V, Jamerson K. The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial. J Cardiometab Syndr. 2008; 3(4):229-33. View in: PubMed

  553. Phillips RA, Fonseca V, Katholi RE, McGill JB, Messerli FH, Bell DS, Raskin P, Wright JT, Iyengar M, Anderson KM, Lukas MA, Bakris GL. Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study. J Cardiometab Syndr. 2008; 3(4):211-7. View in: PubMed

  554. Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008 Nov 25; 52(22):1749-57. View in: PubMed

  555. Dronavalli S, Bakris GL. Mechanistic insights into diuretic-induced insulin resistance. Hypertension. 2008 Dec; 52(6):1009-11. View in: PubMed

  556. Bakris GL, Sowers JR. ASH position paper: treatment of hypertension in patients with diabetes-an update. J Clin Hypertens (Greenwich). 2008 Sep; 10(9):707-13; discussion 714-5. View in: PubMed

  557. Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation. 2008 Oct 14; 118(16):1643-50. View in: PubMed

  558. Norris KC, Shlipak MG, Bakris G. KEEP launches follow-up initiative aimed at predicting the future. Nephrol News Issues. 2008 Sep; 22(10):44-6. View in: PubMed

  559. Bakris GL. Albuminuria reduction and nephropathy progression. Curr Hypertens Rep. 2008 Oct; 10(5):388-9. View in: PubMed

  560. Bakris GL. Should a lower blood pressure goal and albuminuria reduction be mandated to slow hypertensive nephropathy? Curr Hypertens Rep. 2008 Oct; 10(5):387-8. View in: PubMed

  561. Blankstein R, Bakris GL. Changes in kidney function following heart failure treatment: focus on renin-angiotensin system blockade. Heart Fail Clin. 2008 Oct; 4(4):425-38. View in: PubMed

  562. Blankstein R, Bakris GL. Renal hemodynamic changes in heart failure. Heart Fail Clin. 2008 Oct; 4(4):411-23. View in: PubMed

  563. Bakris G, Böhm M, Dagenais G, Diener HC, Fujita T, Gorelick P, Kjeldsen SE, Laakso M, Mancia G, Pitt B, Sharma A, Sleight P, Teo K, Unger T, Weber M, Williams B, Zannad F. Cardiovascular protection for all individuals at high risk: evidence-based best practice. Clin Res Cardiol. 2008 Oct; 97(10):713-25. View in: PubMed

  564. Sarafidis PA, Bakris GL. Renin-angiotensin blockade and kidney disease. Lancet. 2008 Aug 16; 372(9638):511-2. View in: PubMed

  565. Duka I, Bakris G. Influence of microalbuminuria in achieving blood pressure goals. Curr Opin Nephrol Hypertens. 2008 Sep; 17(5):457-63. View in: PubMed

  566. Alper AB, Campbell RC, Anker SD, Bakris G, Wahle C, Love TE, Hamm LL, Mujib M, Ahmed A. A propensity-matched study of low serum potassium and mortality in older adults with chronic heart failure. Int J Cardiol. 2009 Sep 11; 137(1):1-8. View in: PubMed

  567. Bakris GL, Weber MA. Appropriate dose transition to a controlled-release formulation of carvedilol in patients with hypertension. Rev Cardiovasc Med. 2008; 9(2):96-105. View in: PubMed

  568. McCullough PA, Li S, Jurkovitz CT, Stevens L, Collins AJ, Chen SC, Norris KC, McFarlane S, Johnson B, Shlipak MG, Obialo CI, Brown WW, Vassalotti J, Vassaloti J, Whaley-Connell AT, Brenner RM, Bakris GL. Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. Am Heart J. 2008 Aug; 156(2):277-83. View in: PubMed

  569. Saab G, Whaley-Connell AT, McCullough PA, Bakris GL. CKD awareness in the United States: the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2008 Aug; 52(2):382-3. View in: PubMed

  570. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab. 2008 Aug; 4(8):444-52. View in: PubMed

  571. Kjeldsen SE, Jamerson KA, Bakris GL, Pitt B, Dahlöf B, Velazquez EJ, Gupte J, Staikos L, Hua TA, Shi V, Hester A, Tuomilehto J, Ostergren J, Ibsen H, Weber M. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. Blood Press. 2008; 17(1):7-17. View in: PubMed

  572. Bell DS, Bakris GL, McGill JB. Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients. Diabetes Obes Metab. 2009 Mar; 11(3):234-8. View in: PubMed

  573. Bakris G, Stockert J, Molitch M, Zhou Q, Champion A, Bacher P, Sowers J. Risk factor assessment for new onset diabetes: literature review. Diabetes Obes Metab. 2009 Mar; 11(3):177-87. View in: PubMed

  574. Filippatos GS, Adamopoulos C, Sui X, Love TE, Pullicino PM, Lubsen J, Bakris G, Anker SD, Howard G, Kremastinos DT, Ahmed A. A propensity-matched study of hypertension and increased stroke-related hospitalization in chronic heart failure. Am J Cardiol. 2008 Jun 15; 101(12):1772-6. View in: PubMed

  575. Carter BL, Einhorn PT, Brands M, He J, Cutler JA, Whelton PK, Bakris GL, Brancati FL, Cushman WC, Oparil S, Wright JT. Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. Hypertension. 2008 Jul; 52(1):30-6. View in: PubMed

  576. Vasisht KP, Bakris G. New onset diabetes: can it be delayed? J Hum Hypertens. 2008 Aug; 22(8):517-9. View in: PubMed

  577. Bakris G, Burgess E, Weir M, Davidai G, Koval S. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 2008 Aug; 74(3):364-9. View in: PubMed

  578. Bakris GL, Weir MR. Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression. Postgrad Med. 2008 Apr; 120(1):33-42. View in: PubMed

  579. Bakris G, Fonseca V, Foody J. Challenges to the diagnosis, evaluation, treatment, and management of clustered cardiometabolic risk factors. J Cardiometab Syndr. 2008; 3(2):119-25. View in: PubMed

  580. Gradman AH, Weir MR, Bakris GL. Newer combination therapies in the management of hypertension: an update. J Clin Hypertens (Greenwich). 2008 May; 10(5):398-405. View in: PubMed

  581. Appel LJ, Wright JT, Greene T, Kusek JW, Lewis JB, Wang X, Lipkowitz MS, Norris KC, Bakris GL, Rahman M, Contreras G, Rostand SG, Kopple JD, Gabbai FB, Schulman GI, Gassman JJ, Charleston J, Agodoa LY. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med. 2008 Apr 28; 168(8):832-9. View in: PubMed

  582. Sarafidis PA, Li S, Chen SC, Collins AJ, Brown WW, Klag MJ, Bakris GL. Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med. 2008 Apr; 121(4):332-40. View in: PubMed

  583. Drexler AJ, Nesto RW, Abrahamson MJ, Bakris G, Bell D, Brunzell J, Dandona P, Davidson J, Fonseca V, Fowler M, Frye R, Giles T, Haffner S, Hollenberg N, Hsueh W, Law R, Plutzky J, Ratner R, Reusch J, Selwyn A, Sowers J, Wyne K, Young LH. Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome. Metab Syndr Relat Disord. 2005; 3(2):147-73. View in: PubMed

  584. Astor BC, Yi S, Hiremath L, Corbin T, Pogue V, Wilkening B, Peterson G, Lewis J, Lash JP, Van Lente F, Gassman J, Wang X, Bakris G, Appel LJ, Contreras G. N-terminal prohormone brain natriuretic peptide as a predictor of cardiovascular disease and mortality in blacks with hypertensive kidney disease: the African American Study of Kidney Disease and Hypertension (AASK). Circulation. 2008 Apr 01; 117(13):1685-92. View in: PubMed

  585. McFarlane SI, Chen SC, Whaley-Connell AT, Sowers JR, Vassalotti JA, Salifu MO, Li S, Wang C, Bakris G, McCullough PA, Collins AJ, Norris KC. Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2008 Apr; 51(4 Suppl 2):S46-55. View in: PubMed

  586. Rao MV, Qiu Y, Wang C, Bakris G. Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. Am J Kidney Dis. 2008 Apr; 51(4 Suppl 2):S30-7. View in: PubMed

  587. Bakris G, Collins AJ. Executive summary: Kidney Early Evaluation Program (KEEP) 2007 Annual Data Report. Am J Kidney Dis. 2008 Apr; 51(4 Suppl 2):S1-2. View in: PubMed

  588. Bakris GL, Toto RD, McCullough PA, Rocha R, Purkayastha D, Davis P. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008 Jun; 73(11):1303-9. View in: PubMed

  589. Hart P, Bakris GL. Calcium antagonists: Do they equally protect against kidney injury? Kidney Int. 2008 Apr; 73(7):795-6. View in: PubMed

  590. Bakris G, Molitch M, Zhou Q, Sarafidis P, Champion A, Bacher P, Sowers JR. Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study. J Cardiometab Syndr. 2008; 3(1):18-25. View in: PubMed

  591. Weber MA, Bakris GL, Giles TD, Messerli FH. Beta-blockers in the treatment of hypertension: new data, new directions. J Clin Hypertens (Greenwich). 2008 Mar; 10(3):234-8. View in: PubMed

  592. Bakris GL, Berkwits M. Trials that matter: the effect of a fixed-dose combination of an Angiotensin-converting enzyme inhibitor and a diuretic on the complications of type 2 diabetes. Ann Intern Med. 2008 Mar 04; 148(5):400-1. View in: PubMed

  593. Sarafidis P, Bogojevic Z, Basta E, Kirstner E, Bakris GL. Comparative efficacy of two different beta-blockers on 24-hour blood pressure control. J Clin Hypertens (Greenwich). 2008 Feb; 10(2):112-8. View in: PubMed

  594. Weir MR, Bakris GL. Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come? J Clin Hypertens (Greenwich). 2008 Feb; 10(2):146-52. View in: PubMed

  595. Sarafidis PA, Bakris GL. State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension. J Clin Hypertens (Greenwich). 2008 Feb; 10(2):130-9. View in: PubMed

  596. Giles TD, Bakris GL, Weber MA. Beta-blocker therapy in hypertension: a need to pause and reflect. J Am Coll Cardiol. 2008 Jan 29; 51(4):516-7; author reply 517-8. View in: PubMed

  597. Duru OK, Li S, Jurkovitz C, Bakris G, Brown W, Chen SC, Collins A, Klag M, McCullough PA, McGill J, Narva A, Pergola P, Singh A, Norris K. Race and sex differences in hypertension control in CKD: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2008 Feb; 51(2):192-8. View in: PubMed

  598. Tarif N, Bakris G. The place for calcium channel blockers in the treatment of hypertension in patients with diabetes mellitus. Saudi J Kidney Dis Transpl. 2000 Oct-Dec; 11(4):531-6. View in: PubMed

  599. Bakris GL. Slowing nephropathy progression: focus on proteinuria reduction. Clin J Am Soc Nephrol. 2008 Jan; 3 Suppl 1:S3-10. View in: PubMed

  600. Bakris GL. Lifestyle changes and unanswered questions about hypertension and cardiovascular risk. Curr Hypertens Rep. 2007 Nov; 9(5):392. View in: PubMed

  601. Bakris GL, Sowers JR, Ferdinand KC. Blood pressure control in the patient with difficult-to-control hypertension: which agent for which patient? Prev Cardiol. 2008; 11(1):42-9. View in: PubMed

  602. Bakris GL. Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker. J Clin Hypertens (Greenwich). 2008 Jan; 10(1 Suppl 1):27-32. View in: PubMed

  603. Cushman WC, Neutel JM, Saunders E, Bakris GL, Ferdinand KC, Ofili EO, Sowers JR, Madder R, Weber MA. Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy. Am J Geriatr Cardiol. 2008 Jan-Feb; 17(1):27-36. View in: PubMed

  604. Li S, Chen SC, Shlipak M, Bakris G, McCullough PA, Sowers J, Stevens L, Jurkovitz C, McFarlane S, Norris K, Vassalotti J, Klag MJ, Brown WW, Narva A, Calhoun D, Johnson B, Obialo C, Whaley-Connell A, Becker B, Collins AJ. Low birth weight is associated with chronic kidney disease only in men. Kidney Int. 2008 Mar; 73(5):637-42. View in: PubMed

  605. Duka I, Bakris GL. Should all patients with type 2 diabetes receive initial combination therapy: an assessment of the ADVANCE trial. Pol Arch Med Wewn. 2007 Sep; 117(9):389-90. View in: PubMed

  606. Stafylas PC, Sarafidis PA, Lasaridis AN, Tsakni E, Niakas DA, Dombros NV, Grekas DM, Bakris GL. Cost-effectiveness of losartan in diabetic nephropathy: a Greek perspective. J Nephrol. 2007 Nov-Dec; 20(6):703-15. View in: PubMed

  607. Sarafidis PA, Riehle J, Bogojevic Z, Basta E, Chugh A, Bakris GL. A comparative evaluation of various methods for microalbuminuria screening. Am J Nephrol. 2008; 28(2):324-9. View in: PubMed

  608. Wright JT, Bakris GL, Bell DS, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Holdbrook FK, Lukas MA, Iyengar M. Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial. J Clin Hypertens (Greenwich). 2007 Nov; 9(11):842-9. View in: PubMed

  609. Karthikeyan VJ, Bakris G, MacFadyen RJ. The ADVANCE trial: further PROGRESS with HOPE. J Hum Hypertens. 2007 Dec; 21(12):911-3. View in: PubMed

  610. Black HR, Bakris GL, Weber MA, Weiss R, Shahawy ME, Marple R, Tannoury G, Linas S, Wiens BL, Linseman JV, Roden R, Gerber MJ. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich). 2007 Oct; 9(10):760-9. View in: PubMed

  611. Bhatnagar V, O'Connor DT, Schork NJ, Salem RM, Nievergelt CM, Rana BK, Smith DW, Bakris GL, Middleton JP, Norris KC, Wright JT, Cheek D, Hiremath L, Contreras G, Appel LJ, Lipkowitz MS. Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial. J Hypertens. 2007 Oct; 25(10):2082-92. View in: PubMed

  612. Hart PD, Bakris GL. Should beta-blockers be used to control hypertension in people with chronic kidney disease? Semin Nephrol. 2007 Sep; 27(5):555-64. View in: PubMed

  613. Sowers JR, Bakris GL, Black HR, Giles TD. The cardiometabolic syndrome and calcium channel blocker combination drugs. J Cardiometab Syndr. 2007; 2(3):207-12. View in: PubMed

  614. Chugh A, Bakris GL. Pulse pressure and arterial stiffness: an emerging renal risk predictor? J Hypertens. 2007 Sep; 25(9):1796-7. View in: PubMed

  615. Bakris G, Hill M, Mancia G, Steyn K, Black HR, Pickering T, De Geest S, Ruilope L, Giles TD, Morgan T, Kjeldsen S, Schiffrin EL, Coenen A, Mulrow P, Loh A, Mensah G. Achieving blood pressure goals globally: five core actions for health-care professionals. A worldwide call to action. J Hum Hypertens. 2008 Jan; 22(1):63-70. View in: PubMed

  616. Bakris GL. Protein kinase C-beta inhibition: a promise not yet fulfilled. Clin J Am Soc Nephrol. 2007 Jul; 2(4):619-20. View in: PubMed

  617. Khosla N, Bakris G. Lessons learned from recent hypertension trials about kidney disease. Clin J Am Soc Nephrol. 2006 Mar; 1(2):229-35. View in: PubMed

  618. Whaley-Connell A, Pavey BS, Afroze A, Bakris GL. Obesity and insulin resistance as risk factors for chronic kidney disease. J Cardiometab Syndr. 2006; 1(3):209-14; quiz 215-6. View in: PubMed

  619. Sarafidis PA, Bakris GL. Insulin resistance, hyperinsulinemia, and hypertension: an epidemiologic approach. J Cardiometab Syndr. 2006; 1(5):334-42; quiz 343. View in: PubMed

  620. Sarafidis PA, Whaley-Connell A, Sowers JR, Bakris GL. Cardiometabolic syndrome and chronic kidney disease: what is the link? J Cardiometab Syndr. 2006; 1(1):58-65. View in: PubMed

  621. Bakris GL, Ruilope L, Locatelli F, Ptaszynska A, Pieske B, de Champlain J, Weber MA, Raz I. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int. 2007 Oct; 72(7):879-85. View in: PubMed

  622. Roberts WC, Black HR, Bakris GL, Mason RP, Giles TD, Sulkes DJ. The editor's roundtable: revisiting the role of beta blockers in hypertension. Am J Cardiol. 2007 Jul 15; 100(2):253-67. View in: PubMed

  623. Jamerson K, Bakris GL, Dahlöf B, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Kjeldsen SE, Cushman W, Papademetriou V, Weber M. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press. 2007; 16(2):80-6. View in: PubMed

  624. Ruilope L, Kjeldsen SE, de la Sierra A, Mancia G, Ruggenenti P, Stergiou GS, Bakris GL, Giles TD. The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension. Blood Press. 2007; 16(2):72-9. View in: PubMed

  625. Mancia G, Messerli F, Bakris G, Zhou Q, Champion A, Pepine CJ. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension. 2007 Aug; 50(2):299-305. View in: PubMed

  626. Bakris GL. Current perspectives on hypertension and metabolic syndrome. J Manag Care Pharm. 2007 Jun; 13(5 Suppl):S3-5. View in: PubMed

  627. Bakris GL, Gonzalez ER. Case study: the link between hypertension and diabetes. J Manag Care Pharm. 2007 Jun; 13(5 Suppl):S17-9. View in: PubMed

  628. Bakris GL. Pharmacological augmentation of endothelium-derived nitric oxide synthesis. J Manag Care Pharm. 2007 Jun; 13(5 Suppl):S9-12. View in: PubMed

  629. Messerli FH, Bell DS, Fonseca V, Katholi RE, McGill JB, Phillips RA, Raskin P, Wright JT, Bangalore S, Holdbrook FK, Lukas MA, Anderson KM, Bakris GL. Body weight changes with beta-blocker use: results from GEMINI. Am J Med. 2007 Jul; 120(7):610-5. View in: PubMed

  630. McCullough PA, Jurkovitz CT, Pergola PE, McGill JB, Brown WW, Collins AJ, Chen SC, Li S, Singh A, Norris KC, Klag MJ, Bakris GL. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2007 Jun 11; 167(11):1122-9. View in: PubMed

  631. Sarafidis PA, McFarlane SI, Bakris GL. Antihypertensive agents, insulin sensitivity, and new-onset diabetes. Curr Diab Rep. 2007 Jun; 7(3):191-9. View in: PubMed

  632. Bakris GL. ACE inhibitors and ARBs: are they better than other agents to slow nephropathy progression? J Clin Hypertens (Greenwich). 2007 Jun; 9(6):413-5. View in: PubMed

  633. Smith TR, Philipp T, Vaisse B, Bakris GL, Wernsing M, Yen J, Glazer R. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich). 2007 May; 9(5):355-64. View in: PubMed

  634. Weber MA, Bakris GL, Dahlöf B, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Weir M, Kjeldsen S, Massie B, Nesbitt S, Ofili E, Jamerson K. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press. 2007; 16(1):13-9. View in: PubMed

  635. Fonseca V, Bakris GL, Bell DS, McGill JB, Raskin P, Messerli FH, Phillips RA, Katholi RE, Wright JT, Waterhouse B, Lukas MA, Anderson KM. Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. Diabet Med. 2007 Jul; 24(7):759-63. View in: PubMed

  636. Sarafidis PA, Lasaridis AN, Nilsson PM, Pikilidou MI, Stafilas PC, Kanaki A, Kazakos K, Yovos J, Bakris GL. Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley's indices in patients with hypertension and type II diabetes. J Hum Hypertens. 2007 Sep; 21(9):709-16. View in: PubMed

  637. McGill JB, Bakris GL, Fonseca V, Raskin P, Messerli FH, Phillips RA, Katholi RE, Wright JT, Iyengar M, Anderson KM, Lukas MA, Dalal MR, Bell DS. beta-blocker use and diabetes symptom score: results from the GEMINI study. Diabetes Obes Metab. 2007 May; 9(3):408-17. View in: PubMed

  638. Bogojevic Z, Bakris GL. Albuminuria and cardiovascular risk. Heart Fail Clin. 2006 Jan; 2(1):53-9. View in: PubMed

  639. Chugh A, Bakris GL. Microalbuminuria: what is it? Why is it important? What should be done about it? An update. J Clin Hypertens (Greenwich). 2007 Mar; 9(3):196-200. View in: PubMed

  640. Bakris GL, Weir MR, Black HR. Improving blood pressure control rates: is there more we can do? J Clin Hypertens (Greenwich). 2007 Feb; 9(2):134-42. View in: PubMed

  641. Ahmed A, Rich MW, Sanders PW, Perry GJ, Bakris GL, Zile MR, Love TE, Aban IB, Shlipak MG. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol. 2007 Feb 01; 99(3):393-8. View in: PubMed

  642. Bakris G, Dickholtz M, Meyer PM, Kravitz G, Avery E, Miller M, Brown J, Woodfield C, Bell B. Atlas vertebra realignment and achievement of arterial pressure goal in hypertensive patients: a pilot study. J Hum Hypertens. 2007 May; 21(5):347-52. View in: PubMed

  643. Sarafidis PA, Bakris GL. The antinatriuretic effect of insulin: an unappreciated mechanism for hypertension associated with insulin resistance? Am J Nephrol. 2007; 27(1):44-54. View in: PubMed

  644. Gilbert RE, Kim SA, Tuttle KR, Bakris GL, Toto RD, McGill JB, Haney DJ, Kelly DJ, Anderson PW. Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes. Diabetes Care. 2007 Apr; 30(4):995-6. View in: PubMed

  645. Robinson JG, Bakris G, Torner J, Stone NJ, Wallace R. Is it time for a cardiovascular primary prevention trial in the elderly? Stroke. 2007 Feb; 38(2):441-50. View in: PubMed

  646. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007 Jan 02; 115(1):114-26. View in: PubMed

  647. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007 Jan; 30(1):162-72. View in: PubMed

  648. Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis. 2007 Jan; 49(1):12-26. View in: PubMed

  649. Sarafidis PA, Bakris GL. Are antihypertensive drugs associated with an increased risk of incident type 2 diabetes? Nat Clin Pract Endocrinol Metab. 2007 Jan; 3(1):8-9. View in: PubMed

  650. Weber MA, Bakris GL, Tarka EA, Iyengar M, Fleck R, Sica DA. Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension. J Clin Hypertens (Greenwich). 2006 Dec; 8(12):840-9. View in: PubMed

  651. Sarafidis PA, Bakris GL. Metabolic effects of beta-blockers: importance of dissociating newer from conventional agents. J Hypertens. 2007 Jan; 25(1):249-52; author reply 252-3. View in: PubMed

  652. Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K, Bacher P, Sowers J. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006 Dec; 29(12):2592-7. View in: PubMed

  653. Sarafidis PA, Bakris GL. Review: Insulin and endothelin: an interplay contributing to hypertension development? J Clin Endocrinol Metab. 2007 Feb; 92(2):379-85. View in: PubMed

  654. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007 Jan; 71(1):31-8. View in: PubMed

  655. Sarafidis PA, Bakris GL. Non-esterified fatty acids and blood pressure elevation: a mechanism for hypertension in subjects with obesity/insulin resistance? J Hum Hypertens. 2007 Jan; 21(1):12-9. View in: PubMed

  656. Bakris GL, Tarka EA, Waterhouse B, Goulding MR, Madan A, Anderson KM, St John Sutton M, Miller AB, Reichek N. Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile. Am J Cardiol. 2006 Oct 02; 98(7A):46L-52L. View in: PubMed

  657. Weber MA, Sica DA, Tarka EA, Iyengar M, Fleck R, Bakris GL. Controlled-release carvedilol in the treatment of essential hypertension. Am J Cardiol. 2006 Oct 02; 98(7A):32L-38L. View in: PubMed

  658. Bakris GL, Hart P, Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int. 2006 Dec; 70(11):1905-13. View in: PubMed

  659. Cooper-Dehoff R, Cohen JD, Bakris GL, Messerli FH, Erdine S, Hewkin AC, Kupfer S, Pepine CJ. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol. 2006 Oct 01; 98(7):890-4. View in: PubMed

  660. Bakris G. The continuum of blood pressure risk: when is the best time to intervene? Curr Hypertens Rep. 2006 Oct; 8(5):395-7. View in: PubMed

  661. Bakris GL, Ruilope LM, McMorn SO, Weston WM, Heise MA, Freed MI, Porter LE. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens. 2006 Oct; 24(10):2047-55. View in: PubMed

  662. Khosla N, Sarafidis PA, Bakris GL. Microalbuminuria. Clin Lab Med. 2006 Sep; 26(3):635-53, vi-vii. View in: PubMed

  663. Sarafidis PA, McFarlane SI, Bakris GL. Gender disparity in outcomes of care and management for diabetes and the metabolic syndrome. Curr Diab Rep. 2006 Jun; 6(3):219-24. View in: PubMed

  664. Messerli FH, Bakris GL, Ferrera D, Houston MC, Petrella RJ, Flack JM, Sun W, Lee E, Neutel JM. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens (Greenwich). 2006 Aug; 8(8):571-81; quiz 582-3. View in: PubMed

  665. Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int. 2006 Oct; 70(7):1223-33. View in: PubMed

  666. Sowers JR, Neutel JM, Saunders E, Bakris GL, Cushman WC, Ferdinand KC, Ofili EO, Weber MA. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich). 2006 Jul; 8(7):470-80. View in: PubMed

  667. Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension. 2006 Aug; 48(2):219-24. View in: PubMed

  668. Sarafidis PA, Bakris GL. Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease. Nephrol Dial Transplant. 2006 Sep; 21(9):2366-74. View in: PubMed

  669. Sarafidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM. 2006 Jul; 99(7):431-6. View in: PubMed

  670. Jones-Burton C, Mishra SI, Fink JC, Brown J, Gossa W, Bakris GL, Weir MR. An in-depth review of the evidence linking dietary salt intake and progression of chronic kidney disease. Am J Nephrol. 2006; 26(3):268-75. View in: PubMed

  671. Lim HS, MacFadyen RJ, Bakris G, Lip GY. The role of hyperglycaemia and the hypercoagulable state in the pathogenesis of cardiovascular events in diabetes mellitus: implications for hypertension management. Curr Pharm Des. 2006; 12(13):1567-79. View in: PubMed

  672. Bakris GL, Ruilope L, Locatelli F, Ptaszynska A, Pieske B, Raz I, Voors AA, Dechamplain J, Weber MA. Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial. J Hum Hypertens. 2006 Sep; 20(9):693-700. View in: PubMed

  673. Sarafidis PA, Bakris GL. Do the metabolic effects of beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension? J Clin Hypertens (Greenwich). 2006 May; 8(5):351-6; quiz 357-8. View in: PubMed

  674. Sarafidis PA, Bakris GL. Antihypertensive therapy and the risk of new-onset diabetes. Diabetes Care. 2006 May; 29(5):1167-9. View in: PubMed

  675. Ofili EO, Ferdinand KC, Saunders E, Neutel JM, Bakris GL, Cushman WC, Sowers JR, Weber MA. Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy. J Natl Med Assoc. 2006 Apr; 98(4):618-26. View in: PubMed

  676. Weber MA, White WB, Giles TD, Bakris GL, Neutel JM, Smith DH, Davidai G. An effectiveness study comparing algorithm-based antihypertensive therapy with previous treatments using conventional and ambulatory blood pressure measurements. J Clin Hypertens (Greenwich). 2006 Apr; 8(4):241-50; quiz 251-2. View in: PubMed

  677. Sarafidis PA, Bakris GL. Are beta blockers passé for the treatment of hypertension? J Clin Hypertens (Greenwich). 2006 Apr; 8(4):239-40. View in: PubMed

  678. Milchak JL, Carter BL, Ardery G, Black HR, Bakris GL, Jones DW, Kreiter CD. Development of explicit criteria to measure adherence to hypertension guidelines. J Hum Hypertens. 2006 Jun; 20(6):426-33. View in: PubMed

  679. Sarafidis PA, Bakris GL. Level of kidney function determines cardiovascular fate after coronary bypass graft surgery. Circulation. 2006 Feb 28; 113(8):1046-7. View in: PubMed

  680. White WB, Giles T, Bakris GL, Neutel JM, Davidai G, Weber MA. Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. Am Heart J. 2006 Jan; 151(1):176-84. View in: PubMed

  681. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli F, Phillips RA, Raskin P, Wright JT, Waterhouse B, Lukas MA, Anderson KM, Bell DS. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension. 2005 Dec; 46(6):1309-15. View in: PubMed

  682. Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care. 2005 Nov; 28(11):2686-90. View in: PubMed

  683. Bakris GL, Smith DH, Giles TD, White WB, Davidai G, Weber MA. Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients. J Clin Hypertens (Greenwich). 2005 Oct; 7(10):587-95; quiz 596-7. View in: PubMed

  684. Neutel JM, Saunders E, Bakris GL, Cushman WC, Ferdinand KC, Ofili EO, Sowers JR, Weber MA. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich). 2005 Oct; 7(10):578-86. View in: PubMed

  685. Choi KL, Bakris GL. Hypertension treatment guidelines: practical implications. Semin Nephrol. 2005 Jul; 25(4):198-209. View in: PubMed

  686. Nathan S, Pepine CJ, Bakris GL. Calcium antagonists: effects on cardio-renal risk in hypertensive patients. Hypertension. 2005 Oct; 46(4):637-42. View in: PubMed

  687. Mishra SI, Jones-Burton C, Fink JC, Brown J, Bakris GL, Weir MR. Does dietary salt increase the risk for progression of kidney disease? Curr Hypertens Rep. 2005 Oct; 7(5):385-91. View in: PubMed

  688. Bakris G. Clinical trials report. Combination drug treatment for hypertension with nondiabetic renal disease. Curr Hypertens Rep. 2005 Oct; 7(5):358-9. View in: PubMed

  689. Bakris G. Clinical trials report. Proteinuria and blood pressure reduction: are they of equal importance to preserve kidney function? Curr Hypertens Rep. 2005 Oct; 7(5):357-8. View in: PubMed

  690. Ruilope LM, Rosei EA, Bakris GL, Mancia G, Poulter NR, Taddei S, Unger T, Volpe M, Waeber B, Zannad F. Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press. 2005; 14(4):196-209. View in: PubMed

  691. Bakris G. Proteinuria: a link to understanding changes in vascular compliance? Hypertension. 2005 Sep; 46(3):473-4. View in: PubMed

  692. Russo CJ, Melista E, Cui J, DeStefano AL, Bakris GL, Manolis AJ, Gavras H, Baldwin CT. Association of NEDD4L ubiquitin ligase with essential hypertension. Hypertension. 2005 Sep; 46(3):488-91. View in: PubMed

  693. Khosla N, Chua DY, Elliott WJ, Bakris GL. Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications? J Clin Hypertens (Greenwich). 2005 Jun; 7(6):354-6. View in: PubMed

  694. Garg JP, Ellis R, Elliott WJ, Hasabou N, Chua D, Chertow GM, Bakris GL. Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study. Am J Nephrol. 2005 Jul-Aug; 25(4):393-9. View in: PubMed

  695. Bakris G. Is ethnicity a factor in choice of antihypertensive drug? Postgrad Med. 2005 May; 117(5):40. View in: PubMed

  696. Preston RA, White WB, Pitt B, Bakris G, Norris PM, Hanes V. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens. 2005 Jun; 18(6):797-804. View in: PubMed

  697. White WB, Weber MA, Davidai G, Neutel JM, Bakris GL, Giles T. Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial. Blood Press Monit. 2005 Jun; 10(3):157-63. View in: PubMed

  698. Winer N, Folker A, Murphy JA, Hung E, Bard M, Perkelvald A, Sowers JR, Bakris GL. Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetes. Prev Cardiol. 2005; 8(2):87-92. View in: PubMed

  699. Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, Rostand SG, Miller E, Smith W, Bakris GL. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med. 2005 Apr 25; 165(8):947-53. View in: PubMed

  700. Bakris GL. Protecting renal function in the hypertensive patient: clinical guidelines. Am J Hypertens. 2005 Apr; 18(4 Pt 2):112S-119S. View in: PubMed

  701. Bakris GL. Preventing hypertensive kidney disease: the critical role of combination therapy. Am J Hypertens. 2005 Apr; 18(4 Pt 2):93S-94S. View in: PubMed

  702. Bakris G. George Bakris, MD: researching ways to combat hypertension. Interview by Mike Mitka. JAMA. 2005 Mar 23; 293(12):1439. View in: PubMed

  703. El-Achkar TM, Ohmit SE, McCullough PA, Crook ED, Brown WW, Grimm R, Bakris GL, Keane WF, Flack JM. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney Int. 2005 Apr; 67(4):1483-8. View in: PubMed

  704. Bakris GL, Bell DS, Fonseca V, Katholi R, McGill J, Phillips R, Raskin P, Wright JT, Iyengar M, Holeslaw T, Anderson KM. The rationale and design of the Glycemic Effects in Diabetes Mellitus Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial. J Diabetes Complications. 2005 Mar-Apr; 19(2):74-9. View in: PubMed

  705. McFarlane SI, Castro J, Kaur J, Shin JJ, Kelling D, Farag A, Simon N, El-Atat F, Sacerdote A, Basta E, Flack J, Bakris G, Sowers JR. Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to men. J Clin Hypertens (Greenwich). 2005 Feb; 7(2):73-80. View in: PubMed

  706. Bakris GL. ACE inhibitor for a diabetic patient with normal blood pressure? Postgrad Med. 2005 Jan; 117(1):6. View in: PubMed

  707. Bakris GL, Bank AJ, Kass DA, Neutel JM, Preston RA, Oparil S. Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process. Am J Hypertens. 2004 Dec; 17(12 Pt 2):23S-30S. View in: PubMed

  708. Abbott KC, Trespalacios FC, Agodoa LY, Taylor AJ, Bakris GL. beta-Blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Arch Intern Med. 2004 Dec 13-27; 164(22):2465-71. View in: PubMed

  709. Bakris GL. Implications of albuminuria on kidney disease progression. J Clin Hypertens (Greenwich). 2004 Nov; 6(11 Suppl 3):18-22. View in: PubMed

  710. Busby DE, Bakris GL. Comparison of commonly used assays for the detection of microalbuminuria. J Clin Hypertens (Greenwich). 2004 Nov; 6(11 Suppl 3):8-12. View in: PubMed

  711. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT, Oakes R, Lukas MA, Anderson KM, Bell DS. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004 Nov 10; 292(18):2227-36. View in: PubMed

  712. Bakris G. Inclusion of albuminuria in hypertension and heart guidelines. Kidney Int Suppl. 2004 Nov; (92):S124-5. View in: PubMed

  713. Bakris GL, Toto RD, McCullough PA. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. J Hum Hypertens. 2005 Feb; 19(2):139-44. View in: PubMed

  714. Bakris GL, Gaxiola E, Messerli FH, Mancia G, Erdine S, Cooper-DeHoff R, Pepine CJ. Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension. 2004 Nov; 44(5):637-42. View in: PubMed

  715. Jamerson KA, Bakris GL, Wun CC, Dahlöf B, Lefkowitz M, Manfreda S, Pitt B, Velazquez EJ, Weber MA. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens. 2004 Sep; 17(9):793-801. View in: PubMed

  716. Bakris GL. Clinical importance of microalbuminuria in diabetes and hypertension. Curr Hypertens Rep. 2004 Oct; 6(5):352-6. View in: PubMed

  717. McCullough PA, Bakris GL, Owen WF, Klassen PS, Califf RM. Slowing the progression of diabetic nephropathy and its cardiovascular consequences. Am Heart J. 2004 Aug; 148(2):243-51. View in: PubMed

  718. Fox JC, Leight K, Sutradhar SC, Demopoulos LA, Gleim GW, Lewin AJ, Bakris GL. The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy. J Clin Hypertens (Greenwich). 2004 Aug; 6(8):437-42; quiz 443-4. View in: PubMed

  719. Chua DY, Bakris GL. Clinical implications of blockade of the renin-angiotensin system in management of hypertension. Contrib Nephrol. 2004; 143:105-16. View in: PubMed

  720. Chrysant SG, Bakris GL. Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. Am J Hypertens. 2004 Jul; 17(7):590-6. View in: PubMed

  721. Hart PD, Bakris GL. Hypertension control rates: time for translation of guidelines into clinical practice. Am J Med. 2004 Jul 01; 117(1):62-4. View in: PubMed

  722. Gashti CN, Bakris GL. The role of calcium antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens. 2004 Mar; 13(2):155-61. View in: PubMed

  723. Bakris G. How to adjust ACE inhibitors and ARBs in diabetes? Postgrad Med. 2004 May; 115(5):9-10. View in: PubMed

  724. Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004 Jun; 65(6):1991-2002. View in: PubMed

  725. Khosla N, Hart P, Bakris GL. Management of hypertension in the cardiometabolic syndrome and diabetes. Curr Diab Rep. 2004 Jun; 4(3):199-205. View in: PubMed

  726. Chua DC, Bakris GL. Is proteinuria a plausible target of therapy? Curr Hypertens Rep. 2004 Jun; 6(3):177-81. View in: PubMed

  727. Ruilope LM, Usan L, Segura J, Bakris GL. Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en DIabéticos tipo Dos) study. J Hypertens. 2004 Jan; 22(1):217-22. View in: PubMed

  728. Davidson MB, Bazargan M, Bakris G, Peters Harmel A, Campese V, Basta E. ImmunoDip: an improved screening method for microalbuminuria. Am J Nephrol. 2004 May-Jun; 24(3):284-8. View in: PubMed

  729. Abbott K, Basta E, Bakris GL. Blood pressure control and nephroprotection in diabetes. J Clin Pharmacol. 2004 Apr; 44(4):431-8. View in: PubMed

  730. Bakris GL, Sowers JR. When does new onset diabetes resulting from antihypertensive therapy increase cardiovascular risk. Hypertension. 2004 May; 43(5):941-2. View in: PubMed

  731. Bakris GL. The importance of blood pressure control in the patient with diabetes. Am J Med. 2004 Mar 08; 116 Suppl 5A:30S-38S. View in: PubMed

  732. Mangrum AJ, Bakris GL. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues. Semin Nephrol. 2004 Mar; 24(2):168-75. View in: PubMed

  733. Abbott KC, Bakris GL. What have we learned from the current trials? Med Clin North Am. 2004 Jan; 88(1):189-207. View in: PubMed

  734. Izhar M, Alausa T, Folker A, Hung E, Bakris GL. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. Hypertension. 2004 Mar; 43(3):573-7. View in: PubMed

  735. Chua DY, Bakris GL. Diabetes and chronic kidney disease: tragedy and challenge. Blood Purif. 2004; 22(1):130-5. View in: PubMed

  736. Bakris GL. Hypertension and nephropathy. Am J Med. 2003 Dec 08; 115 Suppl 8A:49S-54S. View in: PubMed

  737. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003 Dec 03; 290(21):2805-16. View in: PubMed

  738. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003 Dec; 42(6):1206-52. View in: PubMed

  739. Garg J, Bakris GL. Are antihypertensive drugs used to maximally reduce cardiovascular risk in dialysis patients? Am J Kidney Dis. 2003 Dec; 42(6):1301-4. View in: PubMed

  740. Abbott KC, Bakris GL. Cardiology patient page. Kidney failure and cardiovascular disease. Circulation. 2003 Oct 21; 108(16):e114-5. View in: PubMed

  741. Weber MA, Bakris GL, Neutel JM, Davidai G, Giles TD. Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker. J Clin Hypertens (Greenwich). 2003 Sep-Oct; 5(5):322-9. View in: PubMed

  742. Eknoyan G, Hostetter T, Bakris GL, Hebert L, Levey AS, Parving HH, Steffes MW, Toto R. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis. 2003 Oct; 42(4):617-22. View in: PubMed

  743. Bakris GL. Role for beta-blockers in the management of diabetic kidney disease. Am J Hypertens. 2003 Sep; 16(9 Pt 2):7S-12S. View in: PubMed

  744. Weinberg MS, Kaperonis N, Bakris GL. How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy? Curr Hypertens Rep. 2003 Oct; 5(5):418-25. View in: PubMed

  745. Bakris GL. Who should be treated with combination therapy as initial treatment for hypertension? J Clin Hypertens (Greenwich). 2003 Jul-Aug; 5(4 Suppl 3):21-8. View in: PubMed

  746. Bakris GL. Achieving blood pressure goals: is fixed-dose combination therapy the answer? J Clin Hypertens (Greenwich). 2003 Jul-Aug; 5(4 Suppl 3):2-3. View in: PubMed

  747. Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med. 2003 Jul 14; 163(13):1555-65. View in: PubMed

  748. Bakris GL, Weir MR. Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich). 2003 May-Jun; 5(3):202-9. View in: PubMed

  749. Appel LJ, Middleton J, Miller ER, Lipkowitz M, Norris K, Agodoa LY, Bakris G, Douglas JG, Charleston J, Gassman J, Greene T, Jamerson K, Kusek JW, Lewis JA, Phillips RA, Rostand SG, Wright JT. The rationale and design of the AASK cohort study. J Am Soc Nephrol. 2003 Jul; 14(7 Suppl 2):S166-72. View in: PubMed

  750. Gassman JJ, Greene T, Wright JT, Agodoa L, Bakris G, Beck GJ, Douglas J, Jamerson K, Lewis J, Kutner M, Randall OS, Wang SR. Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol. 2003 Jul; 14(7 Suppl 2):S154-65. View in: PubMed

  751. Bakris GL, Mensah GA. Pathogenesis and clinical physiology of hypertension. Curr Probl Cardiol. 2003 Feb; 28(2):137-55. View in: PubMed

  752. Giles TD, Bakris GL, Smith DH, Davidai G, Weber MA. Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial. Am J Hypertens. 2003 Jun; 16(6):460-6. View in: PubMed

  753. Trespalacios FC, Taylor AJ, Agodoa LY, Bakris GL, Abbott KC. Heart failure as a cause for hospitalization in chronic dialysis patients. Am J Kidney Dis. 2003 Jun; 41(6):1267-77. View in: PubMed

  754. Garg J, Bakris GL. Treatment of hypertension in patients with renal disease. Cardiovasc Drugs Ther. 2002 Dec; 16(6):503-10. View in: PubMed

  755. Bakris GL. The evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocols. Postgrad Med. 2003 May; 113(5):35-40, 43-4, 50. View in: PubMed

  756. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21; 289(19):2560-72. View in: PubMed

  757. Bakris GL, Sowers JR. Microalbuminuria in diabetes: focus on cardiovascular and renal risk reduction. Curr Diab Rep. 2002 Jun; 2(3):258-62. View in: PubMed

  758. Douglas JG, Bakris GL, Epstein M, Ferdinand KC, Ferrario C, Flack JM, Jamerson KA, Jones WE, Haywood J, Maxey R, Ofili EO, Saunders E, Schiffrin EL, Sica DA, Sowers JR, Vidt DG. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003 Mar 10; 163(5):525-41. View in: PubMed

  759. Bakris G. When to refer patients to a nephrologist? Postgrad Med. 2003 Feb; 113(2):11. View in: PubMed

  760. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens. 2003 Jan; 17(1):7-12. View in: PubMed

  761. Kaperonis N, Bakris G. Blood pressure, antihypertensive therapy and risk for renal injury in African-Americans. Curr Opin Nephrol Hypertens. 2003 Jan; 12(1):79-84. View in: PubMed

  762. Bakris GL, Weir M. ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence. J Clin Hypertens (Greenwich). 2002 Nov-Dec; 4(6):420-3. View in: PubMed

  763. Abbott KC, Bakris GL. Treatment of the diabetic patient: focus on cardiovascular and renal risk reduction. Prog Brain Res. 2002; 139:289-98. View in: PubMed

  764. Wright JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002 Nov 20; 288(19):2421-31. View in: PubMed

  765. Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens. 2002 Nov; 20(11):2257-67. View in: PubMed

  766. Sowers JR, Ferdinand KC, Bakris GL, Douglas JG. Hypertension-related disease in African Americans. Factors underlying disparities in illness and its outcome. Postgrad Med. 2002 Oct; 112(4):24-6, 29-30, 33-4 passim. View in: PubMed

  767. Bakris GL, Ferdinand KC, Douglas JG, Sowers JR. Optimal treatment of hypertension in African Americans. Reaching and maintaining target blood pressure goals. Postgrad Med. 2002 Oct; 112(4):73-4, 77-80, 83-4. View in: PubMed

  768. Douglas JG, Ferdinand KC, Bakris GL, Sowers JR. Barriers to blood pressure control in African Americans. Overcoming obstacles is challenging, but target goals can be attained. Postgrad Med. 2002 Oct; 112(4):51-2, 55, 59-62 passim. View in: PubMed

  769. Bakris GL. Hypertension and diabetes: family physicians' pivotal role. Am Fam Physician. 2002 Oct 01; 66(7):1151-2. View in: PubMed

  770. Bakris G. Comparison of telmisartan vs. valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2002 Jul-Aug; 4(4 Suppl 1):26-31. View in: PubMed

  771. Bakris GL, Mensah GA. Pathogenesis and clinical physiology of hypertension. Cardiol Clin. 2002 May; 20(2):195-206, v. View in: PubMed

  772. Garg JP, Bakris GL. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med. 2002 Feb; 7(1):35-43. View in: PubMed

  773. Moser M, Bakris GL, Black H. Roundtable discussion: problems in the management of hypertension. J Clin Hypertens (Greenwich). 2002 May-Jun; 4(3):207-13. View in: PubMed

  774. Garg J, Messerli AW, Bakris GL. Evaluation and treatment of patients with systemic hypertension. Circulation. 2002 May 28; 105(21):2458-61. View in: PubMed

  775. Garg J, Bakris GL. Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes. Curr Hypertens Rep. 2002 Jun; 4(3):185-90. View in: PubMed

  776. Russo LM, Bakris GL, Comper WD. Renal handling of albumin: a critical review of basic concepts and perspective. Am J Kidney Dis. 2002 May; 39(5):899-919. View in: PubMed

  777. Bakris GL, Smith AC, Richardson DJ, Hung E, Preston R, Goldberg R, Epstein M. Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study. J Hum Hypertens. 2002 Mar; 16(3):185-91. View in: PubMed

  778. Bakris G, Sica D, Ram V, Fagan T, Vaitkus PT, Anders RJ. A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes. Am J Hypertens. 2002 Jan; 15(1 Pt 1):53-7. View in: PubMed

  779. Sica DA, Bakris GL. Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment options. J Clin Hypertens (Greenwich). 2002 Jan-Feb; 4(1):52-7. View in: PubMed

  780. Hogan TJ, Elliott WJ, Seto AH, Bakris GL. Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics. 2002; 20(1):37-47. View in: PubMed

  781. Bakris GL. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med. 2001 Dec 10-24; 161(22):2661-7. View in: PubMed

  782. Basta E, Bakris G. Choices and goals in the treatment of the diabetic hypertensive patient. Curr Hypertens Rep. 2001 Oct; 3(5):387-91. View in: PubMed

  783. Bakris GL. Angiotensin-converting enzyme inhibition to enhance vascular health--clinical and research models. Am J Hypertens. 2001 Aug; 14(8 Pt 2):264S-269S. View in: PubMed

  784. Bakris GL. Microalbuminuria: what is it? Why is it important? What should be done about it? J Clin Hypertens (Greenwich). 2001 Mar-Apr; 3(2):99-102. View in: PubMed

  785. Bakris G, Gradman A, Reif M, Wofford M, Munger M, Harris S, Vendetti J, Michelson EL, Wang R. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J Clin Hypertens (Greenwich). 2001 Jan-Feb; 3(1):16-21. View in: PubMed

  786. Odama U, Bakris G. Target Organ Damage in Hypertension. J Clin Hypertens (Greenwich). 2000 Oct; 2(5):312-318. View in: PubMed

  787. Bakris GL. Maximizing Cardiorenal Benefit in the Management of Hypertension: Achieve Blood Pressure Goals. J Clin Hypertens (Greenwich). 1999 Oct; 1(2):141-147. View in: PubMed

  788. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT, Xu S. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001 Jun 06; 285(21):2719-28. View in: PubMed

  789. Griffin KA, Picken M, Bakris GL, Bidani AK. Comparative effects of selective T- and L-type calcium channel blockers in the remnant kidney model. Hypertension. 2001 May; 37(5):1268-72. View in: PubMed

  790. Bakris GL. Treatment of stage I hypertension and development of renal dysfunction. J Hum Hypertens. 2001 Feb; 15(2):81-4. View in: PubMed

  791. Vora JP, Ibrahim HA, Bakris GL. Responding to the challenge of diabetic nephropathy: the historic evolution of detection, prevention and management. J Hum Hypertens. 2000 Oct-Nov; 14(10-11):667-85. View in: PubMed

  792. Bakris GL, Siomos M, Richardson D, Janssen I, Bolton WK, Hebert L, Agarwal R, Catanzaro D. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int. 2000 Nov; 58(5):2084-92. View in: PubMed

  793. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000 Sep; 36(3):646-61. View in: PubMed

  794. Basta E, Bakris GL. Evolution of drugs that preserve renal function. J Clin Pharmacol. 2000 Sep; 40(9):978-89. View in: PubMed

  795. Koshy S, Bakris GL. Therapeutic approaches to achieve desired blood pressure goals: focus on calcium channel blockers. Cardiovasc Drugs Ther. 2000 Jun; 14(3):295-301. View in: PubMed

  796. Bakris GL, Whelton P, Weir M, Mimran A, Keane W, Schiffrin E. The future of clinical trials in chronic renal disease: outcome of an NIH/FDA/Physician Specialist Conference. Evaluation of Clinical Trial Endpoints in Chronic Renal Disease Study Group. J Clin Pharmacol. 2000 Aug; 40(8):815-25. View in: PubMed

  797. Bakris G. Oral antidiabetic agents safe with renal disease? Postgrad Med. 2000 Jun; 107(7):66. View in: PubMed

  798. Sowers JR, Williams M, Epstein M, Bakris G. Hypertension in patients with diabetes. Strategies for drug therapy to reduce complications. Postgrad Med. 2000 Apr; 107(4):47-54, 60. View in: PubMed

  799. Bidani AK, Griffin KA, Bakris G, Picken MM. Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation. Kidney Int. 2000 Apr; 57(4):1651-61. View in: PubMed

  800. Sowers JR, Bakris GL. Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med. 2000 Mar 30; 342(13):969-70. View in: PubMed

  801. Elliott WJ, Maddy R, Toto R, Bakris G. Hypertension in patients with diabetes. Overcoming barriers to effective control. Postgrad Med. 2000 Mar; 107(3):29-32, 35-6, 38. View in: PubMed

  802. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000 Mar 13; 160(5):685-93. View in: PubMed

  803. Weir MR, Maibach EW, Bakris GL, Black HR, Chawla P, Messerli FH, Neutel JM, Weber MA. Implications of a health lifestyle and medication analysis for improving hypertension control. Arch Intern Med. 2000 Feb 28; 160(4):481-90. View in: PubMed

  804. Bakris G, Sowers J, Epstein M, Williams M. Hypertension in patients with diabetes. Why is aggressive treatment essential? Postgrad Med. 2000 Feb; 107(2):53-6, 61-4. View in: PubMed

  805. Swan S, Elliott WJ, Bakris G. "Clinical pharmacology studies in patients with renal impairment: past experience and regulatory perspectives". J Clin Pharmacol. 2000 Jan; 40(1):7-10. View in: PubMed

  806. Sheinfeld GR, Bakris GL. Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. Am J Hypertens. 1999 Aug; 12(8 Pt 2):80S-85S. View in: PubMed

  807. Bakris GL. When to discontinue ACE inhibitors for nephropathy. Postgrad Med. 1999 Jul; 106(1):29. View in: PubMed

  808. Bakris GL, Lass NA, Glock D. Renal hemodynamics in radiocontrast medium-induced renal dysfunction: A role for dopamine-1 receptors. Kidney Int. 1999 Jul; 56(1):206-10. View in: PubMed

  809. Griffin KA, Picken MM, Bakris GL, Bidani AK. Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int. 1999 May; 55(5):1849-60. View in: PubMed

  810. Rabelink TJ, Bakris GL. The renin-angiotensin system in diabetic nephropathy: the endothelial connection. Miner Electrolyte Metab. 1998; 24(6):381-8. View in: PubMed

  811. Bakris GL. Assessing kidneys that may be fragile. Postgrad Med. 1998 Nov; 104(5):31. View in: PubMed

  812. Bakris GL. The role of combination antihypertensive therapy and the progression of renal disease hypertension: looking toward the next millennium. Am J Hypertens. 1998 Oct; 11(10):158S-162S. View in: PubMed

  813. Villarosa IP, Bakris GL. The Appropriate Blood Pressure Control in Diabetes (ABCD) Trial. J Hum Hypertens. 1998 Sep; 12(9):653-5. View in: PubMed

  814. Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 1998 Oct; 54(4):1283-9. View in: PubMed

  815. Bakris GL. Risks for renal involvement in diabetes. Postgrad Med. 1998 Sep; 104(3):33. View in: PubMed

  816. Smith AC, Toto R, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int. 1998 Sep; 54(3):889-96. View in: PubMed

  817. Bakris GL. Progression of diabetic nephropathy. A focus on arterial pressure level and methods of reduction. Diabetes Res Clin Pract. 1998 Apr; 39 Suppl:S35-42. View in: PubMed

  818. Makrilakis K, Bakris G. Diabetic hypertensive patients: improving their prognosis. J Cardiovasc Pharmacol. 1998; 31 Suppl 2:S34-40. View in: PubMed

  819. Bakris GL. Angiotensin II receptor blockers in hypertension and renal disease. Hosp Pract (1995). 1998 Apr 15; 33(4):19-22. View in: PubMed

  820. Tarif N, Bakris GL. Renal components of the hypertensive syndrome. J Cardiovasc Risk. 1997 Aug; 4(4):271-7. View in: PubMed

  821. Tarif N, Bakris GL. Angiotensin II receptor blockade and progression of nondiabetic-mediated renal disease. Kidney Int Suppl. 1997 Dec; 63:S67-70. View in: PubMed

  822. Tarif N, Bakris GL. Preservation of renal function: the spectrum of effects by calcium-channel blockers. Nephrol Dial Transplant. 1997 Nov; 12(11):2244-50. View in: PubMed

  823. Bakris GL, Kusmirek SL, Smith AC, Gavras I, Gavras H. Calcium antagonism abolishes the antipressor action of vasopressin (V1) receptor antagonism. Am J Hypertens. 1997 Oct; 10(10 Pt 1):1153-8. View in: PubMed

  824. Mangrum A, Bakris GL. Predictors of renal and cardiovascular mortality in patients with non-insulin-dependent diabetes: a brief overview of microalbuminuria and insulin resistance. J Diabetes Complications. 1997 Nov-Dec; 11(6):352-7. View in: PubMed

  825. Bakris GL, Griffin KA, Picken MM, Bidani AK. Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury. J Hypertens. 1997 Oct; 15(10):1181-5. View in: PubMed

  826. Silverman M, Bakris GL. Treatment of renal failure and blood pressure. Curr Opin Nephrol Hypertens. 1997 May; 6(3):237-42. View in: PubMed

  827. Simeon G, Bakris GL. Socioeconomic impact of diabetic nephropathy: can we improve the outcome? J Hypertens Suppl. 1997 Mar; 15(2):S77-82. View in: PubMed

  828. Bakris G, Bursztyn M, Gavras I, Bresnahan M, Gavras H. Role of vasopressin in essential hypertension: racial differences. J Hypertens. 1997 May; 15(5):545-50. View in: PubMed

  829. Bakris G, White D. Effects of an ACE inhibitor combined with a calcium channel blocker on progression of diabetic nephropathy. J Hum Hypertens. 1997 Jan; 11(1):35-8. View in: PubMed

  830. Bakris GL, Messerli FH. The Lanai Symposium: hypertensive patient profiles: approaches to management and disease prevention. J Hum Hypertens. 1997 Jan; 11(1):7-8. View in: PubMed

  831. Kilaru P, Bakris GL. Renal mortality associated with non-insulin-dependent diabetes mellitus. J Diabetes Complications. 1997 Mar-Apr; 11(2):104-11. View in: PubMed

  832. Bakris GL, Mangrum A, Copley JB, Vicknair N, Sadler R. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension. 1997 Mar; 29(3):744-50. View in: PubMed

  833. Bakris GL. Is the level of arterial pressure reduction important for preservation of renal function. Nephrol Dial Transplant. 1996 Dec; 11(12):2383-4. View in: PubMed

  834. Bakris GL, Weir MR. Salt intake and reductions in arterial pressure and proteinuria. Is there a direct link? Am J Hypertens. 1996 Dec; 9(12 Pt 2):200S-206S. View in: PubMed

  835. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996 Nov; 50(5):1641-50. View in: PubMed

  836. Bakris GL, Weir MR, Sowers JR. Therapeutic challenges in the obese diabetic patient with hypertension. Am J Med. 1996 Sep 30; 101(3A):33S-46S. View in: PubMed

  837. Cziraky MJ, Mehra IV, Wilson MD, Bakris GL. Current issues in treating the hypertensive patient with diabetes: focus on diabetic nephropathy. Ann Pharmacother. 1996 Jul-Aug; 30(7-8):791-801. View in: PubMed

  838. Epstein M, Bakris G. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med. 1996 Sep 23; 156(17):1969-78. View in: PubMed

  839. Bakris GL. Microalbuminuria: prognostic implications. Curr Opin Nephrol Hypertens. 1996 May; 5(3):219-23. View in: PubMed

  840. Abbott K, Smith A, Bakris GL. Effects of dihydropyridine calcium antagonists on albuminuria in patients with diabetes. J Clin Pharmacol. 1996 Mar; 36(3):274-9. View in: PubMed

  841. Bakris GL, Smith A. Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intern Med. 1996 Aug 01; 125(3):201-4. View in: PubMed

  842. Lash JP, Bakris GL. Effects of ACE inhibitors and calcium antagonists alone or combined on progression of diabetic nephropathy. Nephrol Dial Transplant. 1995 Oct; 10 Suppl 9:56-62. View in: PubMed

  843. Bakris GL, Williams B. Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ? J Hypertens Suppl. 1995 Aug; 13(2):S95-101. View in: PubMed

  844. Bakris GL. Hypertension in diabetic patients. An overview of interventional studies to preserve renal function. Am J Hypertens. 1993 Apr; 6(4):140S-147S. View in: PubMed

  845. Bakris GL. Diabetic nephropathy. What you need to know to preserve kidney function. Postgrad Med. 1993 Apr; 93(5):89-90, 93-5, 99-100. View in: PubMed

  846. Bakris GL. Angiotensin-converting enzyme inhibitors and progression of diabetic nephropathy. Ann Intern Med. 1993 Apr 15; 118(8):643-4. View in: PubMed

  847. Bakris G. Severe hypertension in a young patient. Hosp Pract (Off Ed). 1993 Oct 15; 28(10):57-64. View in: PubMed

  848. Brown SA, Walton CL, Crawford P, Bakris GL. Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int. 1993 Jun; 43(6):1210-8. View in: PubMed

  849. Slataper R, Vicknair N, Sadler R, Bakris GL. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med. 1993 Apr 26; 153(8):973-80. View in: PubMed

  850. Bakris GL, Stein JH. Diabetic nephropathy. Dis Mon. 1993 Aug; 39(8):573-611. View in: PubMed

  851. Bakris GL, Re RN. Endothelin modulates angiotensin II-induced mitogenesis of human mesangial cells. Am J Physiol. 1993 Jun; 264(6 Pt 2):F937-42. View in: PubMed

  852. Abbott KC, Sanders LR, Bakris GL. Microalbuminuria in non-insulin-dependent diabetes mellitus. Implications for renal survival. Arch Intern Med. 1994 Jan 24; 154(2):146-53. View in: PubMed

  853. Bakris GL, Talbert R. Drug dosing in patients with renal insufficiency. A simplified approach. Postgrad Med. 1993 Dec; 94(8):153-6, 159-60, 163-4. View in: PubMed

  854. Riley DJ, Weir M, Bakris GL. Renal adaptation to the failing heart. Avoiding a 'therapeutic misadventure'. Postgrad Med. 1994 Jun; 95(8):153-6. View in: PubMed

  855. Riley DJ, Weir M, Bakris GL. Renal adaptation to the failing heart. Understanding the cascade of responses. Postgrad Med. 1994 Jun; 95(8):141-6, 149-50. View in: PubMed

  856. Bakris GL, Slataper R, Vicknair N, Sadler R. ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects. J Diabetes Complications. 1994 Jan-Mar; 8(1):2-6. View in: PubMed

  857. Abbott KC, Bakris G. Renal effects of antihypertensive medications: an overview. J Clin Pharmacol. 1993 May; 33(5):392-9. View in: PubMed

  858. Bakris GL, Bhandaru S, Akerstrom V, Re RN. ACE inhibitor-mediated attenuation of mesangial cell growth. A role for endothelin. Am J Hypertens. 1994 Jul; 7(7 Pt 1):583-90. View in: PubMed

  859. Gaber L, Walton C, Brown S, Bakris G. Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidney Int. 1994 Jul; 46(1):161-9. View in: PubMed

  860. Kilaru P, Bakris GL. Microalbuminuria and progressive renal disease. J Hum Hypertens. 1994 Nov; 8(11):809-17. View in: PubMed

  861. Bakris GL, Starke U, Heifets M, Polack D, Smith M, Leurgans S. Renal effects of oral prostaglandin supplementation after ibuprofen in diabetic subjects: a double-blind, placebo-controlled, multicenter trial. J Am Soc Nephrol. 1995 Mar; 5(9):1684-8. View in: PubMed

  862. Hoelscher DD, Weir MR, Bakris GL. Hypertension in diabetic patients: an update of interventional studies to preserve renal function. J Clin Pharmacol. 1995 Jan; 35(1):73-80. View in: PubMed

  863. Hoelscher D, Bakris G. Antihypertensive therapy and progression of diabetic renal disease. J Cardiovasc Pharmacol. 1994; 23 Suppl 1:S34-8. View in: PubMed

  864. Tiwari S, Bakris GL. Psychogenic vertigo: a review. Postgrad Med. 1981 Nov; 70(5):69-71, 74, 77. View in: PubMed

  865. Bakris GL, Cross PD, Hammarsten JE. The use of clonidine for management of opiate abstinence in a chronic pain patient. Mayo Clin Proc. 1982 Oct; 57(10):657-60. View in: PubMed

  866. Bakris GL, Cross PD, Hammarsten JE. Disopyramide-associated liver dysfunction. Mayo Clin Proc. 1983 Apr; 58(4):265-7. View in: PubMed

  867. Bakris GL, Taylor MA, Mulopulos GP, Wawczk S. Lithium prophylaxis and the kidney. J Affect Disord. 1981 Mar; 3(1):37-42. View in: PubMed

  868. Bakris GL, Smith DW, Tiwari S. Dermatologic manifestations of lithium: a review. Int J Psychiatry Med. 1980-1981; 10(4):327-31. View in: PubMed

  869. Zorumski CF, Bakris GL. Choreoathetosis associated with lithium: case report and literature review. Am J Psychiatry. 1983 Dec; 140(12):1621-2. View in: PubMed

  870. Bakris GL, Mulopulos GP, Korchik R, Ezdinli EZ, Ro J, Yoon BH. Pulmonary scar carcinoma. A clinicopathologic analysis. Cancer. 1983 Aug 01; 52(3):493-7. View in: PubMed

  871. Bakris GL. Clonidine for opiate withdrawal in the chronic pain patient. Postgrad Med. 1982 Mar; 71(3):240-1. View in: PubMed

  872. Petruccelli B, Bakris G, Miller T, Korpi ER, Linnoila M. A liquid chromatographic assay for 5-hydroxytryptophan, serotonin and 5-hydroxyindoleacetic acid in human body fluids. Acta Pharmacol Toxicol (Copenh). 1982 Nov; 51(5):421-7. View in: PubMed

  873. Bakris GL, Zorumski CF. Chronic pain. A pharmacologic review and behavior modification approach. Postgrad Med. 1983 May; 73(5):119-23, 126, 128. View in: PubMed

  874. Bakris GL, Mulopulos GP, Tiwari S, Franklin C. An effective alternative for muscle contraction headaches. Orphenadrine citrate. IMJ Ill Med J. 1982 Feb; 161(2):106-8. View in: PubMed

  875. Arend LJ, Bakris GL, Burnett JC, Megerian C, Spielman WS. Role for intrarenal adenosine in the renal hemodynamic response to contrast media. J Lab Clin Med. 1987 Oct; 110(4):406-11. View in: PubMed

  876. Bakris GL, Wilson DM, Burnett JC. The renal, forearm, and hormonal responses to standing in the presence and absence of propranolol. Circulation. 1986 Nov; 74(5):1061-5. View in: PubMed

  877. Bakris GL, Weber RR, Nelson K, Elliott WJ, Kaplan E, Murphy MB. Comparison of the effects of dopamine and fenoldopam, a selective dopamine-1 agonist, on parathyroid hormone release in man. Miner Electrolyte Metab. 1988; 14(6):343-6. View in: PubMed

  878. Bakris GL, Frohlich ED. The evolution of antihypertensive therapy: an overview of four decades of experience. J Am Coll Cardiol. 1989 Dec; 14(7):1595-608. View in: PubMed

  879. Bakris GL, Kern SR. Renal dysfunction resulting from NSAIDs. Am Fam Physician. 1989 Oct; 40(4):199-204. View in: PubMed

  880. Bakris GL, Burnett JC. A role for calcium in radiocontrast-induced reductions in renal hemodynamics. Kidney Int. 1985 Feb; 27(2):465-8. View in: PubMed

  881. Bakris GL, Gaber AO, Jones JD. Oxygen free radical involvement in urinary Tamm-Horsfall protein excretion after intrarenal injection of contrast medium. Radiology. 1990 Apr; 175(1):57-60. View in: PubMed

  882. Sauter ER, Bakris GL. The effects of enalapril on urinary protein excretion in patients with idiopathic membranous nephropathy. J Clin Pharmacol. 1990 Feb; 30(2):155-8. View in: PubMed

  883. Bakris GL, Lass N, Gaber AO, Jones JD, Burnett JC. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol. 1990 Jan; 258(1 Pt 2):F115-20. View in: PubMed

  884. Demarie BK, Bakris GL. Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Intern Med. 1990 Dec 15; 113(12):987-8. View in: PubMed

  885. Porile JL, Bakris GL, Garella S. Acute interstitial nephritis with glomerulopathy due to nonsteroidal anti-inflammatory agents: a review of its clinical spectrum and effects of steroid therapy. J Clin Pharmacol. 1990 May; 30(5):468-75. View in: PubMed

  886. Bakris GL, Sauter ER, Hussey JL, Fisher JW, Gaber AO, Winsett R. Effects of theophylline on erythropoietin production in normal subjects and in patients with erythrocytosis after renal transplantation. N Engl J Med. 1990 Jul 12; 323(2):86-90. View in: PubMed

  887. Bakris GL. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med. 1990 May 01; 112(9):707-8. View in: PubMed

  888. Bakris GL, Fairbanks R, Traish AM. Arginine vasopressin stimulates human mesangial cell production of endothelin. J Clin Invest. 1991 Apr; 87(4):1158-64. View in: PubMed

  889. Bakris GL. The effects of calcium antagonists on renal hemodynamics, urinary protein excretion, and glomerular morphology in diabetic states. J Am Soc Nephrol. 1991 Aug; 2(2 Suppl 1):S21-9. View in: PubMed

  890. Bakris GL. Renal effects of calcium antagonists in diabetes mellitus. An overview of studies in animal models and in humans. Am J Hypertens. 1991 Jul; 4(7 Pt 2):487S-493S. View in: PubMed

  891. Karp S, Bakris G, Cooney A, Rubenstein D, Hou SH. Exfoliative dermatitis secondary to tobramycin sulfate. Cutis. 1991 May; 47(5):331-2. View in: PubMed

  892. Valentino VA, Wilson MD, Weart W, Bakris GL. A perspective on converting enzyme inhibitors and calcium channel antagonists in diabetic renal disease. Arch Intern Med. 1991 Dec; 151(12):2367-72. View in: PubMed

  893. Weir MR, Bakris GL. Risk for renal injury in diabetic hypertensive patients. Pharmacologic approaches. Postgrad Med. 1992 Feb 15; 91(3):87-91, 94-5. View in: PubMed

  894. Weir MR, Bakris GL. Risk for renal injury in diabetic hypertensive patients. The physiologic basis for blood pressure control. Postgrad Med. 1992 Feb 15; 91(3):77-80, 83-4. View in: PubMed

  895. Cook JL, Chen L, Bhandaru S, Bakris GL, Re RN. The use of antisense oligonucleotides to establish autocrine angiotensin growth effects in human neuroblastoma and mesangial cells. Antisense Res Dev. 1992; 2(3):199-210. View in: PubMed

  896. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int. 1992 Apr; 41(4):912-9. View in: PubMed